Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/664—Amides of phosphorus acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/521—Chemokines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/70503—Immunoglobulin superfamily
  • C07K14/70532—B7 molecules, e.g. CD80, CD86
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
  • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/62—DNA sequences coding for fusion proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• This invention generally relates to immunomodulatory compositions and methods for treating diseases such as cancer or infections, in particular to diseases inducing T cell exhaustion, T cell anergy, or both, or diseases where intracellular pathogens, i.e. e.g. Leishmania, evade immune response by upregulating PD-I ligands on APCs (e.g. monocytes, dendritic cells, macrophages) or epithelial cells.
• APCs e.g. monocytes, dendritic cells, macrophages
• epithelial cells e.g. monocytes, dendritic cells, macrophages
• Host resistance to microbial infection integrates two major and overlapping defense systems, innate and adaptive immunity.
• Intracellular pathogens - including viruses, bacteria and parasites - can quickly relay activation signals that stimulate non-specific humoral and cellular effector responses in the infected host early after infection.
• innate defense responses Assisted by these innate defense responses, the rate of microbial growth is delayed for several days, while the adaptive branch of immunity is primed and prompted to confront the pathogens for the long term (adaptive/long-term immunity).
• T cells are mediated by T cells.
• CD4+ helper T cells that produce compounds such as cytokines that stimulate other immune cells to help fight infection early-on, cell mediated responses mediated predominantly by CD 8+ cytotoxic T lymphocytes (CTL) that eliminate pathogen-infected host cells, and antibody responses mediated by T helper cells.
• CTL cytotoxic T lymphocytes
• B7 proteins act to provide a second signal to immune cells (e.g. T cells) that stimulates or inhibits the immune response.
• PD-Ll B7-H1
• PD-L2 PD-DC
• B7-H1 and PD-L2 are inhibitory members of the B7 family of molecules that bind to the common receptor, PD-I.
• PD-Ll is broadly expressed on a wide variety of tissue and cell types, while PD-L2 expression is predominantly restricted to activated dendritic cells (DC) and macrophages.
• PD-I a member of the CD28 family of receptors, is inducibly expressed on activated T cells, B cells, natural killer (NK) cells, monocytes, DC, and macrophages.
• T cell exhaustion has been shown to be caused by inhibitory T cell signaling through the PD-I receptor, which negatively regulates T cell function.
• PD-I ligation by its ligands is to inhibit signaling downstream of the T cell Receptor (TCR). Therefore, signal transduction via PD-I usually provides a suppressive or inhibitory signal to the T cell that results in decreased T cell proliferation or other reduction in T cell activation.
• PD-I signaling is thought to require binding to a PD-I ligand in close proximity to a peptide antigen presented by major histocompatibility complex (MHC), which is bound to the TCR (Freeman Proc. Natl. Acad. Sci. U. S. A 105: 10275-10276 (2008).).
• MHC major histocompatibility complex
• HAV human immunodeficiency virus
• HCV hepatitis C virus
• HSV herpes simplex virus
• C. trachomitis malaria
• Poor primary and effector responses to an antigen/vaccine also poses a problem in cases where rapid immunity is required (even where otherwise effective vaccines can be made), for example during endemic/pandemic outbreaks such as flu, or in the event of a bioterrorism attack with infectious agents (e.g. anthrax), as well as in the pediatric and aging population where immune systems are undeveloped or weakened.
• adjuvants are ingredients added to a vaccine to improve the immune response. Most of the adjuvants that have been developed or are being tested elicit predominantly innate immune responses (not antigen-specific), antibody responses and in very few cases modest T cell responses. None of the adjuvants available induce a potent effector response or rapid T cell proliferation response which is what is required to augment primary responses and elicit protective immunity against intracellular pathogens.
• compositions that provide a more rapid induction of protection as well as robust effector responses against chronic infections.
• compositions and methods for treating infections that induce T cell exhaustion, T cell anergy, or both. It is yet another object of the invention to provide compositions and methods for treating intracellular infections of antigen presenting cells, including monocytes, dendritic cells, macrophages.
• the method and compositions of the invention solve the problem of undesired T cell inhibition by binding to and blocking PD-I to prevent or reduce inhibitory signal transduction, or by binding to and blocking ligands of PD-I such as PD-Ll, thereby preventing (in whole or in part) the ligand from binding to PD-I to deliver an inhibitory signal.
• PD-I antagonists include both compounds that bind directly to PD-I or a ligand such as PD-Ll. In either case, T cell responses, such as T cell proliferation or activation, are increased.
• the PD-I antagonists may bind to and block PD-I ligands expressed on antigen presenting cells (APCs, such as monocytes, macrophages, dendritic cells, epithelial cells etc) which are upregulated by intracellular pathogens.
• APCs antigen presenting cells
• an immune response can be enhanced or augmented: 1) Interfering with molecules that inhibit T cell activity, for example, where the molecule is PD-I, and one either a) blocks the receptor (PD-I) or b) blocks the ligand (B7-H1 or B7-DC), or 2) Augmenting molecules that activate T cell activity, for example, where the molecule is CD28, and an agonist is added.
• the immune response can be modulated by providing antagonists which bind with different affinity (i.e., more or less as required), by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again (similar to what occurs with antigen elicitation using priming and boosting),. In some cases it may be particularly desirable to stimulate the immune system, and then remove the stimulation.
• the affinity of the antagonist for its binding partner can be used to determine the period of time required for dissociation - a higher affinity agent will take longer to dissociate than a lower affinity agent.
• Combinations of antagonists that bind to either PD-I or a ligand, or which bind with different affinities to the same molecule can also be used to modulate the degree of immunostimulation.
• compositions include PD-I antagonists that: (i) bind to and block PD-I without inducing inhibitory signal transduction through PD-I and prevents binding of ligands, such as PD-Ll and PD-L2, thereby preventing activation of the PD-I mediated inhibitory signal; or (ii) bind to ligands of PD-I and prevent binding to the PD-I receptor, thereby preventing activation of the PD-I mediated inhibitory signal.
• ligands such as PD-Ll and PD-L2
• a preferred composition includes an effective amount of a non- antibody PD-I antagonist such as a PD-L2 fusion protein (PD-L2-Ig) to reduce or overcome lack of sufficient T cell responses, T cell exhaustion, T cell anergy, as well as activation of monocytes, macrophages, dendritic cells and other APCs, or all of these effects in a subject.
• PD-I antagonists also include PD-Ll proteins, fragments, variants or fusions thereof that bind to PD-I without triggering inhibitory signal transduction through PD-I. These fragments of PD-Ll are also referred to as non-functional PD-Ll fragments.
• PD-L2 polypeptides, fusion proteins, and non-functional PD-Ll fragments can inhibit or reduce the inhibitory signal transduction that occurs through PD-I in T cells by preventing endogenous ligands of PD-I from interacting with PD-I.
• Additional preferred PD-I antagonists include PD-I or soluble fragments thereof, that bind to ligands of PD-I and prevent binding to the endogenous PD-I receptor on T cells. These fragments of PD-I are also referred to as soluble PD-I fragments.
• Other PD-I antagonists include B7.1 or soluble fragments thereof, that can bind to PD-Ll and prevent binding of PD-Ll to PD-I.
• Additional embodiments include antibodies that bind to and block either the PD-I receptor, without causing inhibitory signal transduction, or ligands of the PD-I receptor, such as PD-Ll and PD-L2.
• the PD-L2 polypeptides, fusion proteins, and non-functional PD-Ll fragments may also activate T cells by binding to another receptor on the T cells or APCs.
• the action of the PD-I antagonists helps overcome T cell exhaustion, T cell anergy, or both, as well as activate monocytes, macrophages, dendritic cells and other APCs induced by infections or cancer.
• Representative infections that can be treated with the PD- L2 polypeptides or fusion proteins include, but are not limited to, infections caused by a virus, bacterium, parasite, protozoan, or fungus.
• Exemplary viral infections that can be treated include, but are not limited to, infections caused by hepatitis virus, human immunodeficiency virus (HIV), human T-lymphotrophic virus (HTLV), herpes virus, influenza, Epstein-Barr virus, filovirus, or a human papilloma virus.
• Other infections that can be treated include those caused by Plasmodium, Mycoplasma, M. tuberculosis, Bacillus anthracis, Staphylococcus, and C. trachomitis.
• the PD-I antagonists can be administered in combination or alternation with a vaccine containing one or more antigens such as viral antigens, bacterial antigens, protozoan antigens, and tumor specific antigens.
• the PD-I antagonists can be used as effective adjuvants with vaccines to increase primary immune responses and effector cell responses in subjects.
• Preferred subjects to be treated have a weakened or compromised immune system, are greater than 65 years old, or are less than 2 years of age.
• Figures IA-B are graphs showing B7-DC-Ig binding to PD-I in a PD-I binding ELISA.
• Figure 2 is a graph showing that B7-DC-Ig binds to PD-I expressing CHO cells.
• Figure 3 is a graph showing that B7-DC-Ig competes with B7-H1 for binding to PD-I.
• Figure 4 shows that B7-DC-Ig combination treatment resulted in generation of antigen- specific memory CTLs in a tumor model.
• Figure 5 shows that B7 -DC-Ig reduced HSV-2 viral particle shedding and enhanced mouse survival in the presence of a HSV-2 vaccine.
• isolated is meant to describe a compound of interest (e.g., either a polynucleotide or a polypeptide) that is in an environment different from that in which the compound naturally occurs e.g. separated from its natural milieu such as by concentrating a peptide to a concentration at which it is not found in nature.
• isolated is meant to include compounds that are within samples that are significantly enriched for the compound of interest and/or in which the compound of interest is partially or significantly purified.
• “Significantly” means statistically signficantly greater.
• polypeptide refers to a chain of amino acids of any length, regardless of modification (e.g., phosphorylation or glycosylation).
• a "variant" polypeptide contains at least one amino acid sequence alteration as compared to the amino acid sequence of the corresponding wild-type polypeptide.
• amino acid sequence alteration can be, for example, a substitution, a deletion, or an insertion of one or more amino acids.
• a "vector” is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment.
• the vectors described herein can be expression vectors.
• an "expression vector” is a vector that includes one or more expression control sequences
• an "expression control sequence” is a DNA sequence that controls and regulates the transcription and/or translation of another DNA sequence.
• "operably linked” means incorporated into a genetic construct so that expression control sequences effectively control expression of a coding sequence of interest.
• fragment of a polypeptide refers to any subset of the polypeptide that is a shorter polypeptide of the full length protein. Generally, fragments will be five or more amino acids in length.
• valency refers to the number of binding sites available per molecule.
• “conservative” amino acid substitutions are substitutions wherein the substituted amino acid has similar structural or chemical properties.
• non-conservative amino acid substitutions are those in which the charge, hydrophobicity, or bulk of the substituted amino acid is significantly altered.
• isolated nucleic acid refers to a nucleic acid that is separated from other nucleic acid molecules that are present in a mammalian genome, including nucleic acids that normally flank one or both sides of the nucleic acid in a mammalian genome.
• isolated includes any non-naturally-occurring nucleic acid sequence, since such non- naturally-occurring sequences are not found in nature and do not have immediately contiguous sequences in a naturally-occurring genome.
• the term "host cell” refers to prokaryotic and eukaryotic cells into which a recombinant expression vector can be introduced.
• transformed and transfected encompass the introduction of a nucleic acid (e.g., a vector) into a cell by a number of techniques known in the art.
• antibody is meant to include both intact molecules as well as fragments thereof that include the antigen-binding site. These include Fab and F(ab') 2 fragments which lack the Fc fragment of an intact antibody.
• immunoe cell is meant a cell of hematopoietic origin and that plays a role in the immune response. Immune cells include lymphocytes (e.g., B cells and T cells), natural killer cells, and myeloid cells (e.g., monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes).
• T cell refers to a CD4+ T cell or a CD8+ T cell
• T cell includes both THl cells, TH2 cells and ThI 7 cells.
• T cell cytoxicity includes any immune response that is mediated by CD 8+ T cell activation.
• exemplary immune responses include cytokine production, CD8+ T cell proliferation, granzyme or perforin production, and clearance of an infectious agent.
• immune cell refers to T cells, B cells, and lymphocytes.
• inhibitory signal transduction refers to signaling through the PD-I receptor by PD-Ll, or any other ligand, having the effect of suppressing, or otherwise reducing, T cell responses, whether by reducing T cell proliferation or by any other inhibitory mechanism. . II. PD-I Antagonists
• a preferred PD-I antagonist compound for interfering with the interaction between PD-I and PD-Ll is PD-L2 (also known as B7-DC), the extracellular domain of PD-L2, fusion proteins of PD-L2, and variants thereof which bind to and block PD-I without triggering inhibitory signal transduction through PD-I, and prevent binding of PD-Ll to PD-I.
• Additional PD-I antagonists include fragments of PD-Ll that bind to PD-I without triggering inhibitory signal transduction through PD-I, PD-I or soluble fragments thereof that bind to ligands of PD-I and prevent binding to the endogenous PD-I receptor on T cells, and B7.1 or soluble fragments thereof that can bind to PD-Ll and prevent binding of PD-Ll to PD-I.
• PD-I antagonists increase T cell cytotoxicity in a subject.
• the multiple functionality PD-I antagonists helps to induce a robust immune response in subjects and overcome T cell exhaustion and T cell anergy.
• PD-I antagonists bind to ligands of PD-I and interfere with or inhibit the binding of the ligands to the PD-I receptor, or bind directly to the PD-I receptor without engaging in signal transduction through the PD-I receptor.
• the PD-I antagonists bind directly to PD-I and block PD-I inhibitory signal transduction.
• the PD-I antagonists bind to ligands of PD-I and reduce or inhibit the ligands from triggering inhibitory signal transduction through the PD- 1.
• the PD-I antagonists can activate T cells by binding to a receptor other than the PD-I receptor.
• the PD-I antagonists can be small molecule antagonists.
• small molecule refers to small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons, preferably between 100 and 2000, more preferably between about 100 and about 1250, more preferably between about 100 and about 1000, more preferably between about 100 and about 750, more preferably between about 200 and about 500 daltons.
• the small molecules often include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more functional groups.
• the small molecule antagonists reduce or interfere with PD-I receptor signal transduction by binding to ligands of PD-I such as PD-Ll and PD-L2 and preventing the ligand from interacting with PD-I or by binding directly to the PD-I receptor without triggering signal transduction through the PD-I receptor.
• Exemplary PD-I antagonists include, but are not limited to, PD-L2, PD-Ll, PD-I or B7-1 polypeptides, and variants, fragments or fusion proteins thereof. Additional embodiments include antibodies that bind to any of these proteins.
• PD-I antagonists bind to PD-I on immune cells and block inhibitory PD-I signaling.
• PD-I signal transduction is thought to require binding to PD- 1 by a PD-I ligand (PD-L2 or PD-Ll; typically PD-Ll) in close proximity to the TCR:MHC complex within the immune synapse. Therefore, proteins, antibodies or small molecules that block inhibitory signal transduction through PD-I and optionally prevent co-ligation of PD-I and TCR on the T cell membrane are useful PD-I antagonists.
• PD-I ligand PD-L2 or PD-Ll; typically PD-Ll
• Representative polypeptide antagonists include, but are not limited to, PD-L2 polypeptides, fragments thereof, fusion proteins thereof, and variants thereof.
• PD-L2 polypeptides that bind to PD-I and block inhibitory signal transduction through PD-I are one of the preferred embodiments.
• Other embodiments include PD-I antagonists that prevent native ligands of PD-I from binding and triggering signal transduction.
• the disclosed PD-L2 polypeptides have reduced or no ability to trigger signal transduction through the PD-I receptor because there is no co-ligation of the TCR by the peptide-MHC complex in the context of the immune synapse. Because signal transduction through the PD-I receptor transmits a negative signal that attenuates T-cell activation and T-cell proliferation, inhibiting the PD-I signal transduction pathway allows cells to be activated that would otherwise be attenuated.
• Murine PD-L2 polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• Human PD-L2 polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• Non-human primate (Cynomolgus) PD-L2 polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• SEQ ID NOs: 1, 3 and 5 each contain a signal peptide.
• PD-I antagonists that bind to the PD-I receptor include, but are not limited to, PD-Ll polypeptides, fragments thereof, fusion proteins thereof, and variants thereof. These PD-I polypeptide antagonists bind to and block the PD-I receptor and have reduced or no ability to trigger inhibitory signal transduction through the PD-I receptor. In one embodiment, it is believed that the PD-Ll polypeptides have reduced or no ability to trigger signal transduction through the PD-I receptor because there is no co-ligation of the TCR by the peptide-MHC complex in the context of the immune synapse.
• Murine PD-Ll polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• Human PD-Ll polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• QRILWDPVT SEHELTCQAE GYPKAEVIWT SSDHQVLSGK TTTTNSKREE KLFbiVTSTLR 180
• SEQ ID NOs: 7 and 9 each contain a signal peptide.
• polypeptides include the PD-I receptor protein, or soluble fragments thereof, which can bind to the PD-I ligands, such as PD- Ll or PD-L2, and prevent binding to the endogenous PD-I receptor, thereby preventing inhibitory signal transduction.
• Such fragments also include the soluble ECD portion of the PD-I protein that optionally includes mutations, such as the A99L mutation, that increases binding to the natural ligands.
• PD-Ll has also been shown to bind the protein B7.1 (Butte, et al., Immunity, 27(1): 111-122 (2007)). Therefore, B7.1 or soluble fragments thereof, which can bind to the PD-Ll ligand and prevent binding to the endogenous PD-I receptor, thereby preventing inhibitory signal transduction, are also useful.
• Murine B7.1 polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• Human B7.1 polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• SEQ ID NOs: 11 and 13 each contain a signal peptide. 3.
• Human PD-I polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• Non-human primate (Cynomolgus) PD-I polypeptides can have at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
• SEQ ID NOs: 15 and 16 each contain a signal peptide.
• the PD-I antagonist polypeptides can be full-length polypeptides, or can be a fragment of a full length polypeptide.
• a fragment of a PD-I antagonist polypeptide refers to any subset of the polypeptide that is a shorter polypeptide of the full length protein.
• a PD-I antagonist polypeptide that is a fragment of full- length PD-I antagonist polypeptide typically has at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 98 percent, 99 percent, 100 percent, or even more than 100 percent of the ability to bind its natural ligand(s) as compared to the full- length PD-I antagonist polypeptide.
• useful fragments of PD-L2 and PD-Ll are those that retain the ability to bind to PD-I.
• PD-L2 and PD-Ll fragments typically have at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 98 percent, 99 percent, 100 percent, or even more than 100 percent of the ability to bind to PD-I as compared to full length PD-L2 and PD-Ll.
• Fragments of PD-I antagonist polypeptides include soluble fragments. Soluble PD-I antagonist polypeptide fragments are fragments of PD-I antagonist polypeptides that may be shed, secreted or otherwise extracted from the producing cells. Soluble fragments of PD-I antagonist polypeptides include some or all of the extracellular domain of the polypeptide, and lack some or all of the intracellular and/or transmembrane domains. In one embodiment, PD-I antagonist polypeptide fragments include the entire extracellular domain of the PD-I antagonist polypeptide. It will be appreciated that the extracellular domain can include 1, 2, 3, 4, or 5 amino acids from the transmembrane domain. Alternatively, the extracellular domain can have 1, 2, 3, 4, or 5 amino acids removed from the C-terminus, N-terminus, or both.
• the PD-I antagonist polypeptides or fragments thereof are expressed from nucleic acids that include sequences that encode a signal sequence.
• the signal sequence is generally cleaved from the immature polypeptide to produce the mature polypeptide lacking the signal sequence.
• the signal sequence of PD-I antagonist polypeptides can be replaced by the signal sequence of another polypeptide using standard molecule biology techniques to affect the expression levels, secretion, solubility, or other property of the polypeptide.
• the signal sequence that is used to replace the PD-I antagonist polypeptide signal sequence can be any known in the art. 1.
• PD-L2 extracellular domains a. Human PD-L2 extracellular domains
• the PD-I antagonist polypeptide includes the extracellular domain of human PD-L2 or a fragment thereof.
• the PD-I antagonist polypeptide can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: atgatctttc ttctcttgat gctgtctttg gaattgcaac ttcaccaaat cgcggccctc 60 ttactgtga ccgtgccaaa agaactgtat atcattgagc acgggtccaa tgtgaccctc 120 gaatgtaact ttgacaccgg cagccacgtt aacctggggg ccatcactgc cagcttgcaa 130 aaagttgaaaacgacacttc acctcaccgg gagagggcaa c
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the human amino acid sequence: MIFLLLMLSL ELQLHQIAAL FTVTVPKELY IIEBGSNVTL
• SEQ ID NO: 19 provides the human amino acid sequence of SEQ ID NO: 18 without the signal sequence:
• the PD-I antagonist polypeptide includes the IgV domain of human PD-L2.
• the first fusion partner can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: tttactgtga ccgtgccaaa agaactgtat atcattgagc acgggtccaa tgtgaccctc 60 gaatgtaact ttgacaccgg cagccacgtt aacctggggg ccatcactgc cagcttgcaa 120 aaagttgaaaacgacacttc acctcaccgg gagagggcaa ccctcttgga ggagcaactg 180 ccattgggga aggcctcttttgggatga gggacag
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the human amino acid sequence:
• the PD-I antagonist polypeptide includes the extracellular domain of non-human primate (Cynomolgus) PD-L2 or a fragment thereof.
• the PD-I antagonist polypeptide can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: atgatcttcc tcctgctaat gttgagcctg gaattgcagc ttcaccagat agcagcttta 60 ttcacagtga cagtccctaa ggaactgtac ataatagagc atggcagcaa tgtgaccctg 120 gaatgcaact ttgacactgg aagtcatgtg aaccttggag caataacagc cagttgcaa 180 aaggtggaaa atgatacatc cccacacc
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the non- human primate amino acid sequence:
• SEQ ID NO:24 provides the non-human primate amino acid sequence of SEQ ID NO:23 without the signal sequence:
• the PD-I antagonist polypeptide includes the IgV domain of non-human primate PD-L2.
• the first fusion partner can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: ttcacagtga cagtccctaa ggaactgtac ataatagagc atggcagcaa tgtgaccctg 60 gaatgcaact ttgacactgg aagtcatgtg aaccttggag caataacagc cagtttgcaa 120 aaggtggaaa atgatacatc cccacaccgt gaaagagcca ctttgctgga ggagcagctg 180 ccctaggga aggcctcgtt ccacatacct caagtccaag tgagggacga aggagg
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the non-human primate amino acid sequence:
• the PD-I antagonist polypeptide includes the extracellular domain of murine PD-L2 or a fragment thereof.
• the PD-I antagonist polypeptide can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: atgctgctcc tgctgccgat actgaacctg agcttacaac ttcatcctgt agcagcttta 60 ttcaccgtga cagcccctaa agaagtgtac accgtagacg tcggcagcag tgtgagcctg 120 gagtgcgatt ttgaccgcag agaatgcact gaactggaag ggataagagc cagtttgcag 180 aaggtagaaa atgatacgtc tctgcaaagt gaaaga
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the murine amino acid sequence: MLLLLPILNL SLQLHPVAAL FTVTAPKEVY TVDVGSSVSL ECDFDRRECT ELEGIRASLQ 60
• SEQ ID NO:29 provides the murine amino acid sequence of SEQ ID NO:28 without the signal sequence:
• the PD-I antagonist polypeptide includes the IgV domain of murine PD-L2.
• the first fusion partner can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: ttcaccgtga cagccctaa agaagtgtac accgtagacg tcggcagcag tgtgagcctg 60 gagtgcgatt ttgaccgcag agaatgcact gaactggaag ggataagagc cagtttgcag 120 aaggtagaaa atgatacgtc tctgcaaagt gaaagagcca ccctgctgga ggagcagctg 180 ccctgggaa aggctttgtt ccacatccct agtgtccaag tgagagat
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the murine amino acid sequence:
• the PD-L2 extracellular domain can contain one or more amino acids from the signal peptide or the putative transmembrane domain of PD-L2. During secretion, the number of amino acids of the signal peptide that are cleaved can vary depending on the expression system and the host. Additionally, fragments of PD-L2 extracellular domain missing one or more amino acids from the C-term ⁇ nus or the N-terminus that retain the ability to bind to PD-I can be used.
• Exemplary suitable fragments of murine PD-L2 that can be used as a first fusion partner include, but are not limited to, the following:
• Additional suitable fragments of murine PD-L2 include, but are not limited to, the following:
• SEQ ID NO:1 optionally with one to five amino acids of a signal peptide attached to the N-terminal end.
• the signal peptide may be any disclosed herein, including the signal peptide contained within SEQ ID NO:1, or may be any signal peptide known in the art.
• Exemplary suitable fragments of human PD-L2 that can be used as a first fusion partner include, but are not limited to, the following: 24-221, 24-220, 24-219, 24-218, 24-217, 24-216, 24-215, 23-221, 23-220, 23-219, 23-218, 23-217, 23-216, 23-215, 22-221, 22-220, 22-219, 22-218, 22-217, 22-216, 22-215, 21-221, 21-220, 21-219, 21-218, 21-217, 21-216, 21-215, 20-221, 20-220, 20-219, 20-218, 20-217, 20-216, 20-215, 19-22I 5 19-220, 19-219, 19-218, 19-217, 19-216, 19-215, 18-221, 18-220, 18-219, 18-218, 18-217, 18-216, 18-215, 17-221, 17-220, 17-219, 17-218, 17-217, 17-216, 17-215, 16-221, 16-220, 16-219, 16-218, 16-217,
• Additional suitable fragments of human PD-L2 include, but are not limited to, the following:
• SEQ ID NO:3 optionally with one to five amino acids of a signal peptide attached to the N-terminal end.
• the signal peptide may be any disclosed herein, including the signal peptide contained within SEQ ID NO:3, or may be any signal peptide known in the art.
• Exemplary suitable fragments of non-human primate PD-L2 that can be used as a first fusion partner include, but are not limited to, the following: 24-221, 24-220, 24-219, 24-218, 24-217, 24-216, 24-215, 23-221, 23-220, 23-219, 23-218, 23-217, 23-216, 23-215, 22-221, 22-220, 22-219, 22-218, 22-217, 22-216, 22-215, 21-221, 21-220, 21-219, 21-218, 21-217, 21-216, 21-215, 20-221, 20-220, 20-219, 20-218, 20-217, 20-216, 20-215, 19-221, 19-220, 19-219, 19-218, 19-217, 19-216, 19-215, 18-221, 18-220, 18-219, 18-218, 18-217, 18-216, 18-215, 17-221, 17-220, 17-219, 17-218, 17-217, 17-216, 17-215, 16-221, 16-220, 16-219, 16-218, 16
• non-human primate PD-L2 include, but are not limited to, the following:
• SEQ ID NO:5 optionally with one to five amino acids of a signal peptide attached to the N-terminal end.
• the signal peptide may be any disclosed herein, including the signal peptide contained within SEQ ID NO:5, or may be any signal peptide known in the art.
• PD-L2 proteins also include a PD-I binding fragment of amino acids 20-121 of SEQ ID NO:3 (human fall length), or amino acids 1-102 of SEQ ID NO:23 (extracellular domain or ECD).
• the PD-L2 polypeptide or PD-I binding fragment also incoiporates amino acids WDYKY at residues 110-114 of SEQ ID NO:3 or WDYKY at residues 91-95 of SEQ ID NO:23.
• such a PD-I binding fragment comprises at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, or at least 100 contiguous amino acids of the sequence of amino acids 20-121 of SEQ ID NO: 3, wherein a preferred embodiment of each such PD-I binding fragment would comprise as a sub-fragment the amino acids WDYKY found at residues 110-114 of SEQ ID NO:3 or WDYKY at residues 91-95 of SEQ ID NO:23
• the variant PD-Ll polypeptide includes all or part of the extracellular domain.
• the amino acid sequence of a representative extracellular domain of PD-Ll can have 80%, 85%, 90%, 95%, or 99% sequence identity to
• QRILWDPVT SEHELTCQAC GYPKAEVIWT SSDHQVLSGK TTTTNSKREE KLFNVTSTLR 180
• the transmembrane domain of PD-Ll begins at amino acid position 239 of SEQ ID NO:9. It will be appreciated that the suitable fragments of PD-Ll can include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 contiguous amino acids of a signal peptide sequence, for example SEQ ID NO:9 or variants thereof, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of the transmembrane domain, or combinations thereof.
• the extracellular domain of murine PD-Ll has the following amino acid sequence
• the transmembrane domain of the murine PD-Ll begins at amino acid position 240 of SEQ ID NO:7.
• the PD-Ll polypeptide includes the extracellular domain of murine PD-Ll with 1, 2, 3, 4 P 5, 6, 7, 8, 9, or 10 contiguous amino acids of a signal peptide, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 contiguous amino acids of the transmembrane domain, or combinations thereof.
• the PD-I antagonist polypeptide includes the extracellular domain of murine B7.1 or a fragment thereof.
• the PD-I antagonist polypeptide can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: atggcttgca attgtcagtt gatgcaggat acaccactcc tcaagtttcc atgtccaagg 60 ctcattcttc tcttgtgct gct gct ctttcacaag tgtcttcaga tgttgatga 120 caactgtcca agtcagtgaa agataggta ttgctgcttt gccttcat 180 gaagatgagt ctgaagaccg aatctactgg caa
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the murine amino acid sequence: MACNCQLMQD TPLLKFPCPR LILLFVLLIR LSQVSSDVDE QLSKSVKDKV LLPCRYMSPH 60
• SEQ ID NO:36 provides the murine amino acid sequence of SEQ ID NO:35 without the signal sequence:
• the PD-I antagonist polypeptide includes the IgV domain of murine B7.1.
• the first fusion partner can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: gttgatgaac aactgtccaa gtcagtgaaa gataaggtat tgctgccttg ccgttaceac 60 tctctcatg aagatgagtc tgaagaccga atctactggc aaaaacatga caaagtggtg 120 ctgtctgtca ttgctgggaa actaaaagtg tggcccgagt ataagaaccg gactttatat 180 gacaacacta cctactctct tatcatcctg ggctggtcc tttttt
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the murine amino acid sequence:
• the PD-I antagonist polypeptide includes the extracellular domain of human B7.1 or a fragment thereof.
• the PD-I antagonist polypeptide can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: atgggccaca cacggaggca gggaacatca ccatccaagt gtccatacct caatttcttt 60 cagctcttgg tgctggctgg tctgg tctttctcac ttctgttcag gtgttatcca cgtgaccaag 120 gaagtgaaag aagtggcaac gctgtcctgt ggtcacaatg tttctgtga agagctggca 180 caaactcgca tctactggca aaaggagaag aaatggtg
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the human amino acid sequence: MI FLLLMLSL ELQLHQIAAL FTVTVPKELY IIEHGSNVTL
• SEQ ID NO:41 provides the human amino acid sequence of SEQ ID NO: 40 without the signal sequence:
• the PD-I antagonist polypeptide includes the IgV domain of human B7.1.
• the first fusion partner can be encoded by a nucleotide sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to: gttatccacg tgaccaagga agtgaaagaa gtggcaacgc tgtcctgtgg tcacaatgtt 60 tctgttgaag agctggcaca aactcgcatc tactggcaaa aggagaagaa aatggtgctg 120 actatgatgt ctggggacat gaatatatgg cccgagtaca agaaccggac catctttgat 180 atcactaata acctctccat tgtgatcctg gcgcc catctgacga gggcacatac
• the PD-I antagonist polypeptide can have at least 80%, 85%, 90%, 95%. 99%, or 100% sequence identity to the human amino acid sequence:
• Exemplary suitable fragments of murine B7.1 that can be used as a costimulatory polypeptide domain include, but are not limited to, the following:
• Additional suitable fragments of murine B7.1 include, but are not limited to, the following:
• the signal peptide may be any disclosed herein, including the signal peptide contained within SEQ ID NO:11, or may be any signal peptide known in the art.
• Exemplary suitable fragments of human B7.1 that can be used as a costimulatory polypeptide domain include, but are not limited to, the following:
• Additional suitable fragments of human B7.1 include, but are not limited to, the following:
• Additional PD-I antagonists include PD-L2 and PD-Ll, polypeptides and fragments thereof that are mutated so that they retain the ability to bind to PD-I under physiological conditions, have increased binding to PD-I, or have decreased ability to promote signal transduction through the PD-I receptor.
• One embodiment provides isolated PD-L2 and PD-Ll polypeptides that contain one or more amino acid substitutions, deletions, or insertions that inhibit or reduce the ability of the polypeptide to activate PD-I and transmit an inhibitory signal to a T cell compared to non-mutated PD-L2 or PD-Ll .
• the PD-L2 and PD-Ll polypeptides may be of any species of origin. In one embodiment, the PD-L2 or PD-Ll polypeptide is from a mammalian species. In a preferred embodiment, the PD-L2 or PD- Ll polypeptide is of human or non-human primate origin.
• the variant PD-L2 or PD-Ll polypeptide has the same binding activity to PD-I as wildtype or non- variant PD-L2 or PD- Ll but does not have or has less than 10% ability to stimulate signal transduction through the PD-I receptor relative to a non-mutated PD-L2 or PD-Ll polypeptide.
• the variant PD-L2 or PD-Ll polypeptide has 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more binding activity to PD-I than wildtype PD-L2 or PD-Ll and has less than 50%, 40%, 30%, 20%, or 10% of the ability to stimulate signal transduction through the PD-I receptor relative to a non-mutated PD-L2 or PD-Ll polypeptide.
• a variant PD-L2 or PD-Ll polypeptide can have any combination of amino acid substitutions, deletions or insertions.
• isolated PD-L2 or PD-Ll variant polypeptides have an integer number of amino acid alterations such that their amino acid sequence shares at least 60, 70, 80, 85, 90, 95, 97, 98, 99, 99.5 or 100% identity with an amino acid sequence of a wild type PD-L2 or PD-Ll polypeptide.
• B7- Hl variant polypeptides have an amino acid sequence sharing at least 60, 70, 80, 85, 90, 95, 97, 98, 99, 99.5 or 100% identity with the amino acid sequence of a wild type murine, non-human primate or human PD-L2 or PD-Ll polypeptide.
• Percent sequence identity can be calculated using computer programs or direct sequence comparison.
• Preferred computer program methods to determine identity between two sequences include, but are not limited to, the GCG program package, FASTA, BLASTP, and TBLASTN (see, e.g., D. W. Mount, 2001, Bioinformatics: Sequence and Genome Analysis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.).
• the BLASTP and TBLASTN programs are publicly available from NCBI and other sources.
• the well-known Smith Waterman algorithm may also be used to determine identity.
• a program useful with these parameters is publicly available as the "gap" program (Genetics Computer Group, Madison, Wis.). The aforementioned parameters are the default parameters for polypeptide comparisons (with no penalty for end gaps).
• polypeptide sequence identity can be calculated using the following equation: % identity - (the number of identical residues)/(alignment length in amino acid residues)* 100. For this calculation, alignment length includes internal gaps but does not include terminal gaps.
• Amino acid substitutions in PD-L2 or PD-Ll polypeptides may be "conservative" or “non-conservative".
• “conservative” amino acid substitutions are substitutions wherein the substituted amino acid has similar structural or chemical properties, and “non-conservative” amino acid substitutions are those in which the charge, hydrophobicity, or bulk of the substituted amino acid is significantly altered. Non-conservative substitutions will differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
• conservative amino acid substitutions include those in which the substitution is within one of the five following groups: 1) small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, GIy); 2) polar, negatively charged residues and their amides (Asp, Asn, GIu, GIn); polar, positively charged residues (His, Arg, Lys); large aliphatic, nonpolar residues (Met, Leu, He, VaI, Cy s); and large aromatic resides (Phe, Tyr, Trp).
• non-conservative amino acid substitutions are those where 1) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; 2) a cysteine or proline is substituted for (or by) any other residue; 3) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or 4) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) a residue that does not have a side chain, e.g., glycine.
• a hydrophilic residue e.g., seryl or threon
• substitutions at the recited amino acid positions can be made using any amino acid or amino acid analog.
• the substitutions at the recited positions can be made with any of the naturally-occurring amino acids (e.g., alanine, aspartic acid, asparagine, arginine, cysteine, glycine, glutamic acid, glutamine, histidine, leucine, valine, isoleucine, lysine, methionine, proline, threonine, serine, phenylalanine, tryptophan, or tyrosine).
• the naturally-occurring amino acids e.g., alanine, aspartic acid, asparagine, arginine, cysteine, glycine, glutamic acid, glutamine, histidine, leucine, valine, isoleucine, lysine, methionine, proline, threonine, serine, phenylalanine, tryptophan, or
• the disclosed isolated variant PD-L2 or PD-Ll polypeptides are antagonists of PD-I and bind to and block PD-I without triggering signal transduction through PD-I .
• the attenuation of T cells by PD-I signal transduction more T cells are available to be activated.
• Preventing T cell inhibition enhances T cell responses, enhances proliferation of T cells, enhances production and/or secretion of cytokines by T cells, stimulates differentiation and effector functions of T cells or promotes survival of T cells relative to T cells not contacted with a PD-I antagonist.
• the T cell response that results from the interaction typically is greater than the response in the absence of the PD-I antagonist polypeptide.
• the response of the T cell in the absence of the PD-I antagonist polypeptide can be no response or can be a response significantly lower than in the presence of the PD-I antagonist polypeptide.
• the response of the T cell can be an effector (e.g., CTL or antibody-producing B cell) response, a helper response providing help for one or more effector (e.g., CTL or antibody-producing B cell) responses, or a suppressive response.
• Methods for measuring the binding affinity between two molecules are well known in the art.
• Methods for measuring the binding affinity of variant PD-L2 or PD-Ll polypeptides for PD-I include, but are not limited to, fluorescence activated cell sorting (FACS) 5 surface plasmon resonance, fluorescence anisotropy, affinity chromatography and affinity selection-mass spectrometry.
• FACS fluorescence activated cell sorting
• variant polypeptides disclosed herein can be full-length polypeptides, or can be a fragment of a full length polypeptide.
• Preferred fragments include all or part of the extracellular domain of effective to bind to PD-I.
• a fragment refers to any subset of the polypeptide that is a shorter polypeptide of the full length protein.
• Additional PD-I antagonists include B7.1 and PD-I polypeptides and fragments thereof that are modified so that they retain the ability to bind to PD-L2 and/or PD-Ll under physiological conditions, or have increased binding binding to PD-L2 and/or PD-Ll .
• Such variant PD-I proteins include the soluble ECD portion of the PD-I protein that includes mutations, such as the A99L mutation, that increases binding to the natural ligands (Molnar et al., Crystal structure of the complex between programmed death- 1 (PD-I) and its ligand PD-L2, PNAS, Vol. 105, pp. 10483-10488 (29 My 2008)).
• the B7.1 and PD-I polypeptides may be of any species of origin.
• the B7.1 or PD-I polypeptide is from a mammalian species.
• the B 7.1 or PD-I polypeptide is of human or non- human primate origin.
• a variant B7.1 or PD-I polypeptide can have any combination of amino acid substitutions, deletions or insertions.
• isolated B7.1 or PD-I variant polypeptides have an integer number of amino acid alterations such that their amino acid sequence shares at least 60, 70, 80, 85, 90, 95, 97, 98, 99, 99.5 or 100% identity with an amino acid sequence of a wild type B7.1 or PD-I polypeptide.
• B7.1 or PD-I variant polypeptides have an amino acid sequence sharing at least 60, 70, 8O 5 85, 90, 95, 97, 98, 99, 99.5 or 100% identity with the amino acid sequence of a wild type murine, non-human primate or human B7.1 or PD-I polypeptide.
• Amino acid substitutions in B7.1 or PD-I polypeptides may be "conservative” or “non-conservative”. Conservative and non-conservative substitutions are described above.
• the disclosed isolated variant B7.1 or PD-I polypeptides are antagonists of PD-I and bind to PD-L2 and/or PD-Ll, thereby blocking their binding to endogenous PD-I .
• the attenuation of T cells by PD-I signal transduction more T cells are available to be activated.
• Preventing T cell inhibition enhances T cell responses, enhances proliferation of T cells, enhances production and/or secretion of cytokines by T cells, stimulates differentiation and effector functions of T cells or promotes survival of T cells relative to T cells not contacted with a PD-I antagonist.
• the T cell response that results from the interaction typically is greater than the response in the absence of the PD-I antagonist polypeptide.
• the response of the T cell in the absence of the PD-I antagonist polypeptide can be no response or can be a response significantly lower than in the presence of the PD-I antagonist polypeptide.
• the response of the T cell can be an effector (e.g., CTL or antibody-producing B cell) response, a helper response providing help for one or more effector (e.g., CTL or antibody- producing B cell) responses, or a suppressive response.
• the variant polypeptides can be full-length polypeptides, or can be a fragment of a full length polypeptide.
• Preferred fragments include all or part of the extracellular domain of effective to bind to PD-L2 and/or PD-Ll.
• a fragment refers to any subset of the polypeptide that is a shorter polypeptide of the full length protein.
• the PD-I antagonists are fusion proteins that contain a first polypeptide domain and a second domain.
• the fusion protein can either bind to a T cell receptor and or preferably the fusion protein can bind to and block inhibitory signal transduction into the T cell, for example by competitively binding to PD-I.
• the disclosed compositions effectively block signal transduction, through PD- 1.
• Suitable costimulatory polypeptides include variant polypeptides and/or fragments thereof that have increased or decreased binding affinity to inhibitory T cell signal transduction receptors such as PD-I.
• the fusion proteins also optionally contain a peptide or polypeptide linker domain that separates the first polypeptide domain from the antigen- binding domain.
• Fusion proteins disclosed herein are of formula I:
• N represents the N-terminus of the fusion protein
• C represents the C-terminus of the fusion protein
• R 1 is a PD-L2, PD-Ll, B7.1, or PD-I polypeptide or a antigen-binding targeting domain
• R 2 is a peptide/polypeptide linker domain
• R 3 is a targeting domain or a antigen-binding targeting domain
• R 3 is a polypeptide domain when “R 1 " is a antigen-binding targeting domain
• R 3 is a antigen- binding targeting domain when “R 1 " is a PD-L2, PD-Ll, B7.1, or PD-I polypeptide domain.
• R 1 " is a PD-L2, PD-Ll , B7.1, or PD-I polypeptide domain
• R 3 is a antigen-binding targeting domain.
• the fusion proteins additionally contain a domain that functions to dimerize or multimerize two or more fusion proteins.
• the domain that functions to dimerize or multimerize the fusion proteins can either be a separate domain, or alternatively can be contained within one of one of the other domains (PD-L2, PD-Ll, B7.1, or PD-I polypeptide domain, antigen-binding targeting domain, or peptide/polypeptide linker domain) of the fusion protein.
• the fusion proteins can be dimerized or multimerized. Dimerization or multimerization can occur between or among two or more fusion proteins through dimerization or multimerization domains. Alternatively, dimerization or multimerization of fusion proteins can occur by chemical crosslinking. The dimers or multimers that are formed can be homodimeric/homomultimeric or heterodimeric/heteromultimeric.
• the fusion proteins also contain antigen-binding targeting domains.
• the targeting domains bind to antigens, ligands or receptors that are specific to immune tissue involved in the regulation of T cell activation in response to infectious disease causing agents.
• the fusion proteins contain a domain that specifically binds to an antigen that is expressed by immune tissue involved in the regulation of T cell activation in response to infectious disease causing agents.
• disease targeting domains are ligands that bind to cell surface antigens or receptors that are specifically expressed on diseased cells or are overexpressed on diseased cells as compared to normal tissue. Diseased cells also secrete a large number of ligands into the microenvironment that affect growth and development. Receptors that bind to ligands secreted by diseased cells, including, but not limited to growth factors, cytokines and chemokines, including the chemokines provided above, are suitable for use in the disclosed fusion proteins.
• Ligands secreted by diseased cells can be targeted using soluble fragments of receptors that bind to the secreted ligands. Soluble receptor fragments are fragments polypeptides that may be shed, secreted or otherwise extracted from the producing cells and include the entire extracellular domain, or fragments thereof.
• disease-associated targeting domains are single polypeptide antibodies that bind to cell surface antigens or receptors that are specifically expressed on diseased cells or are overexpressed on diseased cells as compared to normal tissue.
• Single domain antibodies are described above with respect to coinhibitory receptor antagonist domains.
• Fc domains are described above with respect to coinhibitory receptor antagonist domains.
• disease or disease-associated targeting domains are Fc domains of immunoglobulin heavy chains that bind to Fc receptors expressed on diseased cells.
• the Fc region a includes the polypeptides containing the constant region of an antibody excluding the first constant region immunoglobulin domain.
• Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM.
• the Fc domain is derived from a human or murine immunoglobulin.
• the Fc domain is derived from human IgGl or murine IgG2a including the CH2 and C H 3 regions.
• the hinge, CH2 and C H 3 regions of a human immunoglobulin C ⁇ l chain are encoded by a nucleic acid having at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to: gagcctaagt catgtgacaa gacccatacg tgccc ⁇ ccct gtcccg ⁇ tcc agaactgctg 60 gggggaccta gcgttttctt gttcccccca aagcccaagg acaccctcat gatctcacgg 120 actcccgaag taacatgcgt agtagtcgac gtgagccacg aggatcctga agtgaagttt 180 aattggtacg tggacggagt cgaggtgcat aatgccaaaactaaaact
• the hinge, CH2 and C H 3 regions of a human, immunoglobulin C ⁇ l chain encoded by SEQ ID NO:44 has the following amino acid sequence:
• the hinge, CH2 and C H 3 regions of a murine immunoglobulin C ⁇ 2a chain are encoded by a nucleic acid having at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to: gagccaagag gtcctacgat caagccctgc ccgccttgta aatgcccagc tccaaatttg 60 ctgggtggac cgtcagtcttt tatcttcccg ccaaagataaggacgtctt gattagt 120 ctgagcccca tcgtgac ⁇ tg cgttgtggtg gatgtttcag aggatgaccc cgacgtgcaa 180 atcagttggt tcgttaac ⁇ a cgtggaggtg cataccgctc aaacc
• the hinge, CH2 and CH3 regions of a murine immunoglobulin C ⁇ 2a chain encoded by SEQ ID NO:46 has the following amino acid sequence:
• the Fc domain may contain one or more amino acid insertions, deletions or substitutions that enhance binding to specific Fc receptors that specifically expressed on tumors or tumor-associated neovasculature or are overexpressed on tumors or tumor-associated neovasculature relative to normal tissue.
• Suitable amino acid substitutions include conservative and non-conservative substitutions, as described above.
• rituximab a chimeric mouse/human IgGl monoclonal antibody against CD20
• rituximab a chimeric mouse/human IgGl monoclonal antibody against CD20
• Waldenstrom's macro globulinemia correlated with the individual's expression of allelic variants of Fc ⁇ receptors with distinct intrinsic affinities for the Fc domain of human IgGl.
• Fc ⁇ RIIIA low affinity activating Fc receptor CD16A
• the Fc domain may contain one or more amino acid insertions, deletions or substitutions that reduce binding to the low affinity inhibitory Fc receptor CD32B (Fc ⁇ RIIB) and retain wild-type levels of binding to or enhance binding to the low affinity activating Fc receptor CD16A (Fc ⁇ RIIIA).
• the Fc domain contains amino acid insertions, deletions or substitutions that enhance binding to CDl 6A.
• a large number of substitutions in the Fc domain of human IgGl that increase binding to CD16A and reduce binding to CD32B are known in the art and are described in Stavenhagen, et al., Cancer Res., 57(18):8882-90 (2007).
• Exemplary variants of human IgGl Fc domains with reduced binding to CD32B and/or increased binding to CD16A contain F243L, R929P, Y300L, V305I or P296L substitutions. These amino acid substitutions may be present in a human IgGl Fc domain in any combination.
• the human IgGl Fc domain variant contains a F243L, R929P and Y300L substitution.
• the human IgGl Fc domain variant contains a F243L, R929P, Y300L, V3O5I and P296L substitution.
• disease or disease-associated neovasculature targeting domains are polypeptides that provide a signal for the posttranslational addition of a glycosylphosphatidylinositol (GPI) anchor.
• GPI anchors are glycolipid structures that are added posttranslationally to the C-terminus of many eukaryotic proteins. This modification anchors the attached protein in the outer leaflet of cell membranes.
• GPI anchors can be used to attach T cell receptor binding domains to the surface of cells for presentation Io T cells.
• the GPI anchor domain is C- terminal to the T cell receptor binding domain.
• the GPI anchor domain is a polypeptide that signals for the posttranslational addition addition of a GPI anchor when the polypeptide is expressed in a eukaryotic system.
• Anchor addition is determined by the GPI anchor signal sequence, which consists of a set of small amino acids at the site of anchor addition (the a site) followed by a hydrophilic spacer and ending in a hydrophobic stretch (Low, FASEB J. , 3 : 1600-1608 (1989)). Cleavage of this signal sequence occurs in the ER before the addition of an anchor with conserved central components (Low, FASEBI, 3:1600-1608 (1989)) but with variable peripheral moieties (Homans et al.
• the C-terminus of a GPI- anchored protein is linked through a phosphoethanolamine bridge to the highly conserved core glycan, mannose( ⁇ 1 -2)mannose( ⁇ 1 - ⁇ 6)mannose( ⁇ 1 ⁇ 4)glucosamme( ⁇ 1 - €)myo- inositol.
• a phospholipid tail attaches the GPI anchor to the cell membrane.
• the glycan core can be variously modified with side chains, such as a phosphoethanolamine group, mannose, galactose, sialic acid, or other sugars. The most common side chain attached to the first mannose residue is another mannose.
• lipid anchor of the phosphoinositol ring is a diacylglycerol, an alkylacylglycerol, or a ceramide.
• the lipid species vary in length, ranging from 14 to 28 carbons, and can be either saturated or unsaturated.
• GPI anchors also contain an additional fatty acid, such as palmitic acid, on the 2-hydroxyl of the inositol ring.
• GPI anchor attachment can be achieved by expression of a fusion protein containing a GPI anchor domain in a eukaryotic system capable of carrying out GPI posttranslational modifications.
• GPI anchor domains can be used as the tumor or tumor vasculature targeting domain, or can be additionally added to fusion proteins already containing separate tumor or tumor vasculature targeting domains.
• GPI anchor moieties are added directly to isolated T cell receptor binding domains through an in vitro enzymatic or chemical process.
• GPI anchors can be added to polypeptides without the requirement for a GPI anchor domain.
• GPI anchor moieties can be added to fusion proteins described herein having a T cell receptor binding domain and a tumor or tumor vasculature targeting domain.
• GPI anchors can be added directly to T cell receptor binding domain polypeptides without the requirement for fusion partners encoding tumor or tumor vasculature targeting domains.
• Fusion proteins optionally contain a peptide or polypeptide linker domain that separates the costimulatory polypeptide domain from the antigen-binding targeting domain.
• the linker domain contains the hinge region of an immunoglobulin.
• the hinge region is derived from a human immunoglobulin. Suitable human immunoglobulins that the hinge can be derived from include IgG, IgD and IgA. In a preferred embodiment, the hinge region is derived from human IgG.
• the linker domain contains a hinge region of an immunoglobulin as described above, and further includes one or more additional immunoglobulin domains.
• the additional domain includes the Fc domain of an immunoglobulin.
• the Fc region as used herein includes the polypeptides containing the constant region of an antibody excluding the first constant region immunoglobulin domain.
• Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM.
• the Fc domain is derived from a human immunoglobulin.
• the Fc domain is derived from human IgG including the CH2 and CH3 regions.
• the linker domain contains a hinge region of an immunoglobulin and either the CRI domain of an immunoglobulin heavy chain or the CL domain of an immunoglobulin light chain.
• the CHI or CL domain is derived from a human immunoglobulin.
• the C ⁇ domain may be derived from either a K light chain or a ⁇ light chain.
• the CHI or CL domain is derived from human IgG.
• Amino acid sequences of immunoglobulin hinge regions and other domains are well known in the art.
• Suitable peptide/polypeptide linker domains include naturally occurring or non-naturally occurring peptides or polypeptides.
• Peptide linker sequences are at least 2 amino acids in length.
• the peptide or polypeptide domains are flexible peptides or polypeptides.
• a "flexible linker” refers to a peptide or polypeptide containing two or more amino acid residues joined by peptide bond(s) that provides increased rotational freedom for two polypeptides linked thereby than the two linked polypeptides would have in the absence of the flexible linker. Such rotational freedom allows two or more antigen binding sites joined by the flexible linker to each access target antigen(s) more efficiently.
• Exemplary flexible peptides/polypeptides include, but are not limited to, the amino acid sequences Gly-Ser, Gly-Ser- Gly-Ser (SEQ ID NO:74), Ala-Ser, Gly-Gly-Gly-Ser (SEQ ID NO:75), (GIy 4 -Ser) 3 (SEQ ID NO:76), and (Gly 4 -Ser) 4 (SEQ ID NO:77). Additional flexible peptide/polypeptide sequences are well known in the art.
• the fusion proteins optionally contain a dimerization or multimerization domain that functions to dimerize or multimerize two or more fusion proteins.
• the domain that functions to dimerize or multimerize the fusion proteins can either be a separate domain, or alternatively can be contained within one of the other domains (T cell costimulatory/coinhibitory receptor binding domain, tumor/tumor neovasculature antigen-binding domain, or peptide/polypeptide linker domain) of the fusion protein. Dimerization domains
• a “dimerization domain” is formed by the association of at least two amino acid residues or of at least two peptides or polypeptides (which may have the same, or different, amino acid sequences).
• the peptides or polypeptides may interact with each other through covalent and/or non- covalent associations).
• Preferred dimerization domains contain at least one cysteine that is capable of forming an intermolecular disulfide bond with a cysteine on the partner fusion protein.
• the dimerization domain can contain one or more cysteine residues such that disulfide bond(s) can form between the partner fusion proteins.
• dimerization domains contain one, two or three to about ten cysteine residues.
• the dimerization domain is the hinge region of an immunoglobulin.
• the dimerization domain is contained within the linker peptide/polypeptide of the fusion protein.
• Additional exemplary dimerization domain can be any known in the art and include, but not limited to, coiled coils, acid patches, zinc fingers, calcium hands, a C H I-C L pair, an "interface" with an engineered “knob” and/or “protruberance” as described in U.S. Pat. No. 5,821,333, leucine zippers (e.g., from jun and/or fos) (U.S. Pat. No.
• SH2 src homology 2
• SH3 src Homology 3
• PTB phosphotyrosine binding
• NGF nerve growth factor
• NT-3 neurotrophin-3
• IL-8 interleukin-8
• VEGF vascular endothelial growth factor
• VEGF-C vascular endothelial growth factor
• VEGF-D vascular endothelial growth factor
• PDGF members and brain-derived neurotrophic factor (BDNF)
• BDNF brain-derived neurotrophic factor
• the polypeptide pairs can be identified by methods known in the art, including yeast two hybrid screens. Yeast two hybrid screens are described in U.S. Pat. Nos.
• a “multimerization domain” is a domain that causes three or more peptides or polypeptides to interact with each other through covalent and/or non-covalent association(s).
• Suitable multimerization domains include, but are not limited to, coiled-coil domains.
• a coiled-coil is a peptide sequence with a contiguous pattern of mainly hydrophobic residues spaced 3 and 4 residues apart, usually in a sequence of seven amino acids (heptad repeat) or eleven amino acids (undecad repeat), which assembles (folds) to form a multimeric bundle of helices. Coiled-coils with sequences including some irregular distribution of the 3 and 4 residues spacing are also contemplated.
• Hydrophobic residues are in particular the hydrophobic amino acids VaI, He, Leu, Met, Tyr, Phe and Trp. Mainly hydrophobic means that at least 50% of the residues must be selected from the mentioned hydrophobic amino acids.
• the coiled coil domain may be derived from laminin.
• the heterotrimeric coiled coil protein laminin plays an important role in the formation of basement membranes.
• the multifunctional oligomeric structure is required for laminin function.
• Coiled coil domains may also be derived from the thrombospondins in which three (TSP-I and TSP-2) or five (TSP-3, TSP-4 and TSP-5) chains are connected, or from COMP (COMPcc) (Guo, et at, EMBOJ., 1998, 17: 5265-5272) which folds into a parallel five-stranded coiled coil (Malashkevich ,et al., Science, 274: 761-765 (1996)).
• coiled-coil domains derived from other proteins, and other domains that mediate polypeptide multimerization are known in the art and are suitable for use in the disclosed fusion proteins.
• a representative murine PD-L2 fusion protein is encoded by a nucleic acid having at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to: atgctgctcc tgctgccgat actgaacctg agcttacaac ttcatcctgt agcag ⁇ ttta 60 ttcaccgtga cagcccctaa agaagtgtac accgtagacg tcggcagcag tgtgagcctg 120 gagtgcgatt ttgaccgcag agaatgcact gaactggaag ggataagagc cagtttgcag 180 aaggtagaaa atgatacgtc tctgcaaagt gaaagagcca ccctgctgga ggagcagctg 240 cccctggga
• the murine PD-L2 fusion protein encoded by SEQ ID NO:79 has the following amino acid sequence:
• amino acid sequence of the murine PD-L2 fusion protein of SEQ ID NO: 53 without the signal sequence is:
• a representative human PD-L2 fusion protein is encoded by a nucleic acid having at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to: atgatctttc ttctcttgat gctgtctttg gaattgcaac ttcaccaaat cgcggccctc 60 tttactgtga ccgtgccaaa agaactgtat atcattgagc acgggtccaa tgtgaccctc 120 gaatgtaact ttgacaccgg cagccacgtt aacctggggg ccatcactgc cagcttgcaa 180 aaagttgaaaacgacacttc a ⁇ ctcaccgg gagagggcaa ccctcttgga ggagcaactg 240 ccattgggga aggcctc
• the human PD-L2 fusion protein encoded by SEQ ID NO: 82 has the following amino acid sequence:
• amino acid sequence of the human PD-L2 fusion protein of SEQ ID NO:83 without the signal sequence is:
• a representative non-human primate (Cynomolgus) PD-L2 fusion protein has the following amino acid sequence:
• the amino acid sequence of the non-human primate (Cynomolgus) PD-L2 fusion protein of SEQ ID NO:8 ⁇ without the signal sequence is:
• isolated nucleic acid sequences encoding PD-I antagonist polypeptides, variants thereof and fusion proteins thereof are disclosed.
• isolated nucleic acid refers to a nucleic acid that is separated from other nucleic acid molecules that are present in a mammalian genome, including nucleic acids that normally flank one or both sides of the nucleic acid in a mammalian genome.
• an isolated nucleic acid can be, for example, a DNA molecule, provided one of the nucleic acid sequences normally found immediately flanking that DNA molecule in a naturally-occurring genome is removed or absent.
• an isolated nucleic acid includes, without limitation, a DNA molecule that exists as a separate molecule independent of other sequences (e.g., a chemically synthesized nucleic acid, or a cDNA or genomic DNA fragment produced by PCR or restriction eiidonuclease treatment), as well as recombinant DNA that is incorporated into a vector, an autonomously replicating plasmid, a virus (e.g., a retrovirus, lentivirus, adenovirus, or herpes virus), or into the genomic DNA of a prokaryote or eukaryote.
• a virus e.g., a retrovirus, lentivirus, adenovirus, or herpes virus
• an isolated nucleic acid can include an engineered nucleic acid such as a recombinant DNA molecule that is part of a hybrid or fusion nucleic acid.
• Nucleic acids can be in sense or anti sense orientation, or can be complementary to a reference sequence encoding a PD-L2, PD-Ll, PD-I or B7.1 polypeptide or variant thereof. Reference sequences include, for example, the nucleotide sequence of human PD-L2, human PD-Ll or murine PD-L2 and murine PD-Ll which are known in the art and discussed above.
• Nucleic acids can be DNA, RNA, or nucleic acid analogs. Nucleic acid analogs can be modified at the base moiety, sugar moiety, or phosphate backbone. Such modification can improve, for example, stability, hybridization, or solubility of the nucleic acid. Modifications at the base moiety can include deoxyuridine for deoxythyrnidine, and 5-methyl-2'- deoxycytidine or 5-bromo-2'-deoxycytidine for deoxycytidine. Modifications of the sugar moiety can include modification of the 2' hydroxyl of the ribose sugar to form 2'-O-methyl or 2'-OaIIyI sugars.
• the deoxyribose phosphate backbone can be modified to produce morpholino nucleic acids, in which each base moiety is linked to a six membered, morpholino ring, or peptide nucleic acids, in which the deoxyphosphate backbone is replaced by a pseudopeptide backbone and the four bases are retained. See, for example, Summerton and Weller (1997) Antisense Nucleic Acid Drug Dev. 7:187-195; and Hyrup et al (1996) Bioorgan. Med. Chem. 4:5-23.
• the deoxyphosphate backbone can be replaced with, for example, a phosphorothioate or phosphorodithioate backbone, a phosphoroamidite, or an alkyl phosphotriester backbone.
• Nucleic acids such as those described above, can be inserted into vectors for expression in cells.
• a "vector” is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment.
• Vectors can be expression vectors.
• An "expression vector” is a vector that includes one or more expression control sequences, and an “expression control sequence” is a DNA sequence that controls and regulates the transcription and/or translation of another DNA sequence. Nucleic acids in vectors can be operab ⁇ y linked to one or more expression control sequences.
• operably linked means incorporated into a genetic construct so that expression control sequences effectively control expression of a coding sequence of interest.
• expression control sequences include promoters, enhancers, and transcription terminating regions.
• a promoter is an expression control sequence composed of a region of a DNA molecule, typically within 100 nucleotides upstream of the point at which transcription starts (generally near the initiation site for RNA polymerase II). To bring a coding sequence under the control of a promoter, it is necessary to position the translation initiation site of the translational reading frame of the polypeptide between one and about fifty nucleotides downstream of the promoter. Enhancers provide expression specificity in terms of time, location, and level.
• enhancers can function when located at various distances from the transcription site.
• An enhancer also can be located downstream from the transcription initiation site.
• a coding sequence is "operably linked" and “under the control” of expression control sequences in a cell when RNA polymerase is able to transcribe the coding sequence into niRNA, which then can be translated into the protein encoded by the coding sequence.
• Suitable expression vectors include, without limitation, plasmids and viral vectors derived from, for example, bacteriophage, baculoviruses, tobacco mosaic virus, herpes viruses, cytomegalo virus, retroviruses, vaccinia viruses, adenoviruses, and adeno-associated viruses.
• plasmids and viral vectors derived from, for example, bacteriophage, baculoviruses, tobacco mosaic virus, herpes viruses, cytomegalo virus, retroviruses, vaccinia viruses, adenoviruses, and adeno-associated viruses.
• Numerous vectors and expression systems are commercially available from such corporations as Novagen (Madison, WI), Clontech (Palo Alto, CA), Stratagene (La Jolla, CA), and Invitrogen Life Technologies (Carlsbad, CA).
• An expression vector can include a tag sequence.
• Tag sequences are typically expressed as a fusion with the encoded polypeptide. Such tags can be inserted anywhere within the polypeptide including at either the carboxyl or amino terminus. Examples of useful tags include, but are not limited to, green fluorescent protein (GFP), glutathione S-transferase (GST), polyhistidine, c-myc, hemagglutinin, FlagTM tag (Kodak, New Haven, CT), maltose E binding protein and protein A.
• GFP green fluorescent protein
• GST glutathione S-transferase
• polyhistidine polyhistidine
• c-myc hemagglutinin
• FlagTM tag Kodak, New Haven, CT
• maltose E binding protein and protein A maltose E binding protein and protein A.
• the variant PD-L2 fusion protein is present in a vector containing nucleic acids that encode one or more domains of an Ig heavy chain constant region, preferably having an amino acid sequence corresponding to the hinge, CH 2 and C H3 regions of a human immunoglobulin C ⁇ l chain.
• Vectors containing nucleic acids to be expressed can be transferred into host cells.
• the term "host cell” is intended to include prokaryotic and eukaryotic cells into which a recombinant expression vector can be introduced.
• transformed and “transfected” encompass the introduction of a nucleic acid molecule (e.g., a vector) into a cell by one of a number of techniques. Although not limited to a particular technique, a number of these techniques are well established within the art.
• Prokaryotic cells can be transformed with nucleic acids by, for example, electroporation or calcium chloride mediated transformation.
• Nucleic acids can be transfected into mammalian cells by techniques including, for example, calcium phosphate co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, or microinjection.
• Host cells e.g., a prokaryotic cell or a eukaryotic cell such as a CHO cell
• PD-I antagonist polypeptides described herein can be used to, for example, produce the PD-I antagonist polypeptides described herein.
• Monoclonal and polyclonal antibodies that are reactive with epitopes of the PD-I antagonists, or PD-I are disclosed.
• Monoclonal antibodies (mAbs) and methods for their production and use are described in Kohler and Milstein, Nature 256:495-497 (1975); U.S. Pat. No. 4,376,110; Hartlow, E. et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 1988); Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses, Plenum Press, New York, N. Y. (1980); H. Zola et al., in Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, 1982)).
• Antibodies that bind to PD-I and block signal transduction through PD-I, and which have a lower affinity than those currently in use, allowing the antibody to dissociated in a period of less than three months, two months, one month, three weeks, two weeks,, one week, or a few days after administration, are preferred for enhancement, augmentation or stimulation of an immune response.
• Another embodiment of the invention includes a bi-specific antibody that comprises an antibody that binds to the PD-I receptor bridged to an antibody that binds to a Hgand of PD-I, such as B7-H1.
• the PD-I binding portion reduces or inhibits signal transduction through the PD-I receptor
• Anti-idiotypic antibodies are described, for example, in Idiotypy in Biology and Medicine, Academic Press, New York, 1984; Immunological Reviews Volume 79, 1984; Immunological Reviews Volume 90, 1986; Curr. Top. Microbiol, Immunol. Volume 119, 1985; Bona, C. et al., CRC Crit. Rev. Immunol., pp. 33-81 (1981); Jerme, N K, Ann. Immunol I25C:373-389 (1974); Jerne, N K, In: Idiotypes— Antigens on the Inside, Westen-Schnurr, L, ed., Editiones Roche, Basel, 1982, Urbain, J. et al., Ann. Immunol. 133D:179-(1982); Rajewsky, K. et al., ⁇ w «. Rev. Immunol. 1:569-607 (1983).
• the antibodies may be xenogeneic, allogeneic, syngeneic, or modified forms thereof, such as humanized or chimeric antibodies.
• Antiidiotype antibodies specific for the idiotype of a specific antibody for example an anti-PD-L2 antibody, are also included.
• the term "antibody” is meant to include both intact molecules as well as fragments thereof that include the antigen-binding site and are capable of binding to a PD-I antagonist epitope. These include, Fab and F(ab') 2 fragments which lack the Fc fragment of an intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J Nuc. Med. 24:316-325 (1983)).
• Fv fragments also included are Fv fragments (Hochman, J. el al. (1973) Biochemistry 12:1130-1135; Sharon, J. et al.(1976) Biochemistry 15:1591-1594). These various fragments are produced using conventional techniques such as protease cleavage or chemical cleavage (see, e.g., Rousseaux et al., Meth. Enzymol., 121 :663-69 (1986)).
• Polyclonal antibodies are obtained as sera from immunized animals such as rabbits, goats, rodents, etc. and may be used directly without further treatment or may be subjected to conventional enrichment or purification methods such as ammonium sulfate precipitation, ion exchange chromatography, and affinity chromatography.
• the immunogen may include the complete PD-I antagonist, PD-I, or fragments or derivatives thereof.
• Preferred immunogens include all or a part of the extracellular domain (ECD) of PD-I antagonist or PD-I, where these residues contain the post-translation modifications, such as glycosylation.
• Immunogens including the extracellular domain are produced in a variety of ways known in the art, e.g., expression of cloned genes using conventional recombinant methods or isolation from cells of origin.
• Monoclonal antibodies may be produced using conventional hybridoma technology, such as the procedures introduced by Kohler and Milstein, Nature, 256:495-97 (1975), and modifications thereof (see above references).
• An animal preferably a mouse is primed by immunization with an immunogen as above to elicit the desired antibody response in the primed animal.
• B lymphocytes from the lymph nodes, spleens or peripheral blood of a primed, animal are fused with myeloma cells, generally in the presence of a fusion promoting agent such as polyethylene glycol (PEG).
• PEG polyethylene glycol
• any of a number of murine myeloma cell lines are available for such use: the P3- NSl/l-Ag4-l, P3-x63-k0Ag8.653, Sp2/0-Agl4, or HL1-653 myeloma lines (available from the ATCC 5 Rockville, Md.)-
• Subsequent steps include growth in selective medium so that unfused parental myeloma cells and donor lymphocyte cells eventually die while only the hybridoma cells survive. These are cloned and grown and their supernatants screened for the presence of antibody of the desired specificity, e.g. by immunoassay techniques using PD-L2 or PD-Ll fusion proteins. Positive clones are subcloned, e.g., by limiting dilution, and the monoclonal antibodies are isolated.
• Hybridomas produced according to these methods can be propagated in vitro or in vivo (in ascites fluid) using techniques known in the art (see generally Fink et al., Prog. Clin. Pathol, 9:121-33 (1984)).
• the individual cell line is propagated in culture and the culture medium containing high concentrations of a single monoclonal antibody can be harvested by decantation, filtration, or centrifugation.
• the antibody may be produced as a single chain antibody or scFv instead of the normal multimeric structure.
• Single chain antibodies include the hypervariable regions from an Ig of interest and recreate the antigen binding site of the native Ig while being a fraction of the size of the intact Ig (Skerra, A. et al. Science, 240: 1038-1041 (1988); Pluckthun, A. et al. Methods Enzymol 178: 497-515 (1989); Winter, G. et al. Nature, 349: 293- 299 (1991)).
• the antibody is produced using conventional molecular biology techniques. HI. Methods of Manufacture
• Isolated PD-I antagonists or variants thereof can be obtained by, for example, chemical synthesis or by recombinant production in a host cell.
• a nucleic acid containing a nucleotide sequence encoding the polypeptide can be used to transform, transduce, or transfect a bacterial or eukaryotic host cell (e.g., an insect, yeast, or mammalian cell).
• nucleic acid constructs include a regulatory sequence operably linked to a nucleotide sequence encoding a PD-I antagonist polypeptide.
• Regulatory sequences also referred to herein as expression control sequences typically do not encode a gene product, but instead affect the expression of the nucleic acid sequences to which they are operably linked.
• Useful prokaryotic and eukaryotic systems for expressing and producing polypeptides are well know in the art include, for example, Escherichia coli strains such as BL-21 , and cultured mammalian cells such as CHO cells.
• viral-based expression systems can be utilized to express PD-I antagonist polypeptide.
• Viral based expression systems are well known in the art and include, but are not limited to, baculoviral, SV40, retroviral, or vaccinia based viral vectors.
• Mammalian cell lines that stably express PD-I antagonist polypeptides can be produced using expression vectors with appropriate control elements and a selectable marker.
• the eukaryotic expression vectors pCR3.1 (Invitrogen Life Technologies) and p91023(B) are suitable for expression of variant costimulatory polypeptides in, for example, Chinese hamster ovary (CHO) cells, COS-I cells, human embryonic kidney 293 cells, NIH3T3 cells, BHK21 cells, MDCK cells, and human vascular endothelial cells (HUVEC).
• transfected cells can be cultured such that the polypeptide of interest is expressed, and the polypeptide can be recovered from, for example, the cell culture supernatant or from lysed cells.
• a PD-I antagonist polypeptide can be produced by (a) Ii gating amplified sequences into a mammalian expression vector such as pcDNA3 (Invitrogen Life Technologies), and (b) transcribing and translating in vitro using wheat germ extract or rabbit reticulocyte Iy sate.
• PD-I antagonist polypeptides can be isolated using, for example, chromatographic methods such as DEAE ion exchange, gel filtration, and hydroxylapatite chromatography.
• PD-I antagonist polypeptides in a cell culture supernatant or a cytoplasmic extract can be isolated using a protein G column.
• variant PD-I antagonist polypeptides can be "engineered" to contain an amino acid sequence that allows the polypeptides to be captured onto an affinity matrix.
• a tag such as c-myc s hemagglutinin, polyhistidine, or FlagTM (Kodak) can be used to aid polypeptide purification.
• Such tags can be inserted anywhere within the polypeptide, including at either the carboxyl or amino terminus.
• Other fusions that can be useful include enzymes that aid in the detection of the polypeptide, such as alkaline phosphatase.
• Immunoaffinity chromatography also can be used to purify costimulatory polypeptides.
• Random peptide display libraries can be used to screen for peptides which interact with PD-I, PD-Ll or PD-L2.
• Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., U.S. Patent No. 5,223,409; Ladner et al., U.S. Patent No. 4,946,778; Ladner et al., U.S. Patent No. 5,403,484 and Ladner et al., U.S. Patent No. 5,571,698) and random peptide display libraries and kits for screening such libraries are available commercially.
• Isolated nucleic acid molecules encoding PD-I antagonist polypeptides can be produced by standard techniques, including, without limitation, common molecular cloning and chemical nucleic acid synthesis techniques. For example, polymerase chain reaction (PCR) techniques can be used to obtain an isolated nucleic acid encoding a variant costimulatory polypeptide. PCR is a technique in which target nucleic acids are enzymatically amplified. Typically, sequence information from the ends of the region of interest or beyond can be employed to design oligonucleotide primers that are identical in sequence to opposite strands of the template to be amplified.
• PCR polymerase chain reaction
• PCR can be used to amplify specific sequences from DNA as well as RNA, including sequences from total genomic DNA or total cellular RNA.
• Primers typically are 14 to 40 nucleotides in length, but can range from 10 nucleotides to hundreds of nucleotides in length.
• General PCR techniques are described, for example in PCR Primer: A Laboratory Manual, ed. by Dieffenbach and Dveksler, Cold Spring Harbor Laboratory Press, 1995.
• reverse transcriptase can be used to synthesize a complementary DNA (cDNA) strand.
• Ligase chain reaction, strand displacement amplification, self- sustained sequence replication or nucleic acid sequence-based amplification also can be used to obtain isolated nucleic acids. See, for example, Lewis (1992) Genetic Engineering News 12:1; Guatelli et al (1990) Proc. Natl. Acad. ScI USA 87:1874-1878; and Weiss (1991) Science 254:1292-1293.
• Isolated nucleic acids can be chemically synthesized, either as a single nucleic acid molecule or as a series of oligonucleotides (e.g., using phosphoramidite technology for automated DNA synthesis in the 3' to 5' direction).
• oligonucleotides e.g., >100 nucleotides
• one or more pairs of long oligonucleotides can be synthesized that contain the desired sequence, with each pair containing a short segment of complementarity (e.g., about 15 nucleotides) such that a duplex is formed when the oligonucleotide pair is annealed.
• DNA polymerase can be used to extend the oligonucleotides, resulting in a single, double- stranded nucleic acid molecule per oligonucleotide pair, which then can be ligated into a vector.
• Isolated nucleic acids can also obtained by mutagenesis.
• PD-I antagonist polypeptide encoding nucleic acids can be mutated using standard techniques, including oligonucleo tide-directed mutagenesis and/or site-directed mutagenesis through PCR. See, Short Protocols in Molecular Biology. Chapter 8, Green Publishing Associates and John Wiley & Sons, edited by Ausubel et al, 1992. Examples of amino acid positions thai can be modified include those described herein. IV. Formulations
• compositions including PD-I antagonists are provided.
• Pharmaceutical compositions containing peptides or polypeptides may be for administration by parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), transdermal (either passively or using iontophoresis or electroporation), or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration.
• the compositions may also be administered using bioerodible inserts and may be delivered directly to an appropriate lymphoid tissue (e.g., spleen, lymph node, or mucosal-associated lymphoid tissue) or directly to an organ or tumor.
• the compositions can be formulated in dosage forms appropriate for each route of administration.
• Compositions containing antagonists of PD-I receptors that are not peptides or polypeptides can additionally be formulated for enteral administration.
• the term "effective amount” or “therapeutically effective amount” means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of the disorder being treated or to otherwise provide a desired pharmacologic and/or physiologic effect.
• the precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected.
• Therapeutically effective amounts of PD-I antagonist cause an immune response to be activated, enhanced, augmented, or sustained, and/or overcome or alleviate T cell exhaustion and/or T cell anergy, and/or activate monocytes, macrophages, dendritic cells and other antigen presenting cells ("APCs").
• APCs antigen presenting cells
• the PD-I antagonist is administered in a range of 0.1 - 20 mg/kg based on extrapolation from tumor modeling and bioavailability. A most preferred range is 5-20 mg of PD-I antagonist/kg. Generally, for intravenous injection or infusion, dosage may be lower than when administered by an alternative route. 1. Formulations for Parenteral Administration
• compositions including those containing peptides and polypeptides, are administered in an aqueous solution, by parenteral injection.
• the formulation may also be in the form of a suspension or emulsion.
• pharmaceutical compositions are provided including effective amounts of a peptide or polypeptide, and optionally include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
• compositions include sterile water, buffered saline (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; and optionally, additives such as detergents and solubilizing agents (e.g., TWEEN® 20, TWEEN 80, Polysorbate 8O) 5 antioxidants (e.g., ascorbic acid, sodium metabisulfite), and preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol).
• buffered saline e.g., Tris-HCl, acetate, phosphate
• pH and ionic strength e.g., Tris-HCl, acetate, phosphate
• additives e.g., Tris-HCl, acetate, phosphate
• additives e.g., Tris-HCl, acetate, phosphate
• additives e.g.,
• non-aqueous solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and com oil, gelatin, and injectable organic esters such as ethyl oleate.
• the formulations may be lyophilized and redissolved/resuspended immediately before use.
• the formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
• Controlled Delivery Polymeric Matrices Compositions containing one or more PD-I antagonist or nucleic acids encoding the PD-I antagonist can be administered in controlled release formulations.
• Controlled release polymeric devices can be made for long term release systemically following implantation of a polymeric device (rod, cylinder, film, disk) or injection (microparticles).
• the matrix can be in the form of microparticles such as microspheres, where peptides are dispersed within a solid polymeric matrix or microcapsules, where the core is of a different material than the polymeric shell, and the peptide is dispersed or suspended in the core, which may be liquid or solid in nature. Unless specifically defined herein, microparticles, microspheres, and microcapsules are used interchangeably.
• the polymer may be cast as a thin slab or film, ranging from nanometers to four centimeters, a powder produced by grinding or other standard techniques, or even a gel such as a hydrogel.
• the matrix can also be incorporated into or onto a medical device to modulate an immune response, to prevent infection in an immunocompromised patient (such as an elderly person in which a catheter has been inserted or a premature child) or to aid in healing, as in the case of a matrix used to facilitate healing of pressure sores, decubitis ulcers, etc.
• Either non-biodegradable or biodegradable matrices can be used for delivery of PD-I antagonist or nucleic acids encoding them, although biodegradable matrices are preferred.
• biodegradable matrices may be natural or synthetic polymers, although synthetic polymers are preferred due to the better characterization of degradation and release profiles.
• the polymer is selected based on the period over which release is desired. In some cases linear release may be most useful, although in others a pulse release or "bulk release" may provide more effective results.
• the polymer may be in the form of a hydrogel (typically in absorbing up to about 90% by weight of water), and can optionally be crosslmked with multivalent ions or polymers.
• Bioerodible microspheres can be prepared using any of the methods developed for making microspheres for drug delivery, for example, as described by Mathiowitz and Langer, J. Controlled Release, 5:13-22 (1987); Mathiowitz, et al., Reactive Polymers, 6:275-283 (1987); and Mathiowitz, et al., J Appl. Polymer Set, 35:7 '55-77 '4 (1988).
• Controlled release oral formulations may be desirable. Antagonists of PD-I inhibitory signaling can be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms, e.g., films or gums. Slowly disintegrating matrices may also be incorporated into the formulation.
• Another form of a controlled release is one in which the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects.
• the location of release may be the stomach, the small intestine (the duodenum, the jejunem, or the ileum), or the large intestine.
• the release will avoid the deleterious effects of the stomach environment, either by protection of the active agent (or derivative) or by release of the active agent beyond the stomach environment, such as in the intestine.
• an enteric coating i.e, impermeable to at least pH 5.0
• These coatings may be used as mixed films or as capsules such as those available from Banner Pharmacaps.
• the devices can be formulated for local release to treat the area of implantation or injection and typically deliver a dosage that is much less than the dosage for treatment of an entire body.
• the devices can also be formulated for systemic delivery. These can be implanted or injected subcutaneously.
• Antagonists of PD-I can also be formulated for oral delivery.
• Oral solid dosage forms are known to those skilled in the art. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules or incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 21st Ed. (2005, Lippincott, Williams & Wilins, Baltimore, Md. 21201) pages 889- 964.
• compositions may be prepared in liquid form, or may be in dried powder (e.g., lyophilized) form.
• Liposomal or polymeric encapsulation may be used to formulate the compositions. See also Marshall, K. In: Modem Pharmaceutics Edited by G. S. Banker and C. T. Rhodes Chapter 10, 1979.
• the formulation will include the active agent and inert ingredients which protect the PD-I antagonist in the stomach environment, and release of the biologically active material in the intestine.
• Liquid dosage forms for oral administration including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents.
• Vaccines require strong T cell response to eliminate infected cells.
• PD-I antagonists can be administered as a component of a vaccine to promote, augment, or enhance the primary immune response and effector cell activity and numbers.
• Vaccines include antigens, the PD-I antagonist (or a source thereof) and optionally other adjuvants and targeting molecules.
• Sources of PD-I antagonist include any of the disclosed PD-L2 polypeptides, PD-L2 fusion proteins, variants thereof, PD-Ll fragments, PD-I fragments, nucleic acids encoding PD-L2 polypeptides, PD-L2 fusion proteins, variants thereof, PD-Ll fragments or PD-I fragments, or host cells containing vectors that express polypeptide ligands of PD-I described above. 1. Antigens
• Antigens can be peptides, proteins, polysaccharides, saccharides, lipids, nucleic acids, or combinations thereof.
• the antigen can be derived from a virus, bacterium, parasite, protozoan, fungus, histoplasma, tissue or transformed cell and can be a whole cell or immunogenic component thereof, e.g., cell wall components or molecular components thereof.
• Suitable antigens are known in the art and are available from commercial, government and scientific sources.
• the antigens are whole inactivated or attenuated organisms. These organisms may be infectious organisms, such as viruses, parasites and bacteria.
• the organisms may be tumor cells or cells infected with a virus or intracellular pathogen such as gonorrhea or malaria.
• the antigens may be purified or partially purified polypeptides derived from tumors or viral or bacterial sources.
• the antigens can be recombinant polypeptides produced by expressing DNA encoding the polypeptide antigen in a heterologous expression system.
• the antigens can be DNA encoding all or part of an antigenic protein.
• the DNA may be in the form of vector DNA such as plasmid DNA.
• Antigens may be provided as single antigens or may be provided in combination. Antigens may also be provided as complex mixtures of polypeptides or nucleic acids. i. Viral Antigens
• a viral antigen can be isolated from any virus including, but not limited to, a virus from any of the following viral families: Arenaviridae, Arterivirus, Astroviridae, Baculoviridae, Badnavirus, Barnavi ⁇ dae, Birnaviridae, Bromoviridae, Bunyaviridae, Caliciviridae, Capillovirus, Carlavirus, Caulimovirus, Circovi ⁇ dae, Closterovirus, Comoviridae, Coronaviridae (e.g., Coronavirus, such as severe acute respiratory syndrome (SARS) virus), Corlicoviridae, Cystoviridae, Deltavirus, Dianthovirus, Enatnovirus, Filoviridae (e.g., Marburg virus and Ebola virus (e.g., Zaire, Reston, Ivory Coast, or Sudan strain)), Flaviviridae, (e.g., Hepatitis C virus, Dengue virus 1, Dengue virus 2, Dengue virus 3,
• Viral antigens may be derived from a particular strain, or a combination of strains, such as a papilloma virus, a herpes virus, i.e. herpes simplex 1 and 2; a hepatitis virus, for example, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), the delta hepatitis D virus (HDV) 5 hepatitis E virus (HEV) and hepatitis G virus (HGV), the tick-borne encephalitis viruses; parainfluenza, varicella-zoster, cytonieglavirus, Epstein- Barr, rotavirus, rhinovirus, adenovirus, coxsackieviruses, equine encephalitis, Japanese encephalitis, yellow fever, Rift Valley fever,and lymphocytic choriomeningitis.
• HAV hepatitis A virus
• HBV he
• Bacterial antigens can originate from any bacteria including, but not limited to, Actinomyces, Anabaena, Bacillus, Bacteroides, Bdellovibrio, Bordetella, Borrelia, Campylobacter, Caulobacter, Chlamydia, Chlorobium, Chromatium, Clostridium, Corynebacterium, Cytophaga, Deinococcus, Escherichia, Francisella, Halobacterium, Heliobacter, Haemophilus, Hemophilus influenza type B (HIB), Hyphomicrobium, Legionella, Leptspirosis, Listeria, Meningococcus A, B and C, Methanobacterium, Micrococcus, Myobacterium, Mycoplasma, Myxococcus, Neisseria, Nitrobacter, Oscillatoria, Prochloron, Proteus, Pseudomonas, Phodospi ⁇ llum, Rickettsia, Salmonella, Shi
• Antigens of parasites can be obtained from parasites such as, but not limited to, antigens derived from Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci, Chlamydial trachomatis, Plasmodium falciparum, Trypanosoma brucei, Entamoeba histolytica, Toxoplasma gondii, Trichomonas vaginalis and Schistosoma mansoni.
• parasites such as, but not limited to, antigens derived from Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Ricke
• Sporozoan antigens include Sporozoan antigens, Plasmodian antigens, such as all or part of a Circumsporozoite protein, a Sporozoite surface protein, a liver stage antigen, an apical membrane associated protein, or a Merozoite surface protein.
• Plasmodian antigens such as all or part of a Circumsporozoite protein, a Sporozoite surface protein, a liver stage antigen, an apical membrane associated protein, or a Merozoite surface protein.
• the antigen can be a tumor antigen, including a tumor-associated or tumor-specific antigen, such as, but not limited to, alpha-actinin-4, Bcr-Abl fusion protein, Casp-8, beta-catenin, cdc27, cdk4, cdkn2a, coa-1, dek-can fusion protein, EF2, ET V ⁇ - AMLl fusion protein, LDLR- fucosyltransferaseAS fusion protein, HLA- A2, HLA-Al 1 , hsp70-2, KIAAO205, Mart2, Mum-1, 2, and 3, neo-PAP, myosin class I, OS-9, pml- RAR ⁇ fusion protein, PTPRK 5 K-ras, N-ras, Triosephosphate isomeras, Bage-1, Gage 3,4,5,6,7, GnTV, Herv-K-mel, Lü-1, Mage- Al ,2,3,4,6,10,12, Mag
• the vaccines may include an adjuvant.
• the adjuvant can be, but is not limited to, one or more of the following: oil emulsions (e.g., Freund's adjuvant); saponin formulations; virosomes and viral-like particles; bacterial and microbial derivatives; immuno stimulatory oligonucleotides; ADP-ribosylating toxins and detoxified derivatives; alum; BCG; mineral- containing compositions (e.g., mineral salts, such as aluminium salts and calcium salts, hydroxides, phosphates, sulfates, etc.); bioadhesives and/or mucoadhesives; microparticles; liposomes; polyoxyethylene ether and polyoxyethylene ester formulations; polyphosphazene; muramyl peptides; imidazoquinolone compounds; and surface active substances (e.g. lysolecithin, pluronic polyols, polyanions, peptide
• Adjuvants may also include immunomodulators such as cytokines, interleukins (e.g., IL-I , IL-2, IL-4, IL-5, IL-6, IL-7, IL- 12, etc.), interferons (e.g., interferon-.gamma.), macrophage colony stimulating factor, and tumor necrosis factor.
• immunomodulators such as cytokines, interleukins (e.g., IL-I , IL-2, IL-4, IL-5, IL-6, IL-7, IL- 12, etc.), interferons (e.g., interferon-.gamma.), macrophage colony stimulating factor, and tumor necrosis factor.
• co- stimulatory molecules including other polypeptides of the B7 family, may be administered.
• proteinaceous adjuvants may be provided as the full- length polypeptide or an active fragment thereof, or in the form of DNA, such as plasm id DNA. IV. Methods
• PD-I antagonists and variants thereof, as well as nucleic acids encoding these polypeptides and fusion proteins, or cells expressing PD-I antagonist can be used to enhance a primary immune response to an antigen as well as increase effector cell function such as increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, and stimulating differentiation.
• the PD-I antagonist compositions can be administered to a subject in need thereof in an effective amount to overcome T cell exhaustion and/or T cell anergy. Overcoming T cell exhaustion or T cell anergy can be determined by measuring T cell function using known techniques.
• Preferred PD-I antagonist polypeptides are engineered to bind to PD-I without triggering inhibitory signal transduction through PD-I and retain the ability to costimulate T cells.
• PD-I antagonist in vitro application of the PD-I antagonist can be useful, for example, in basic scientific studies of immune mechanisms or for production of activated T cells for use in studies of T cell function or, for example, passive immunotherapy.
• PD-I antagonist can be added to in vitro assays (e.g., T cell proliferation assays) designed to test for immunity to an antigen of interest in a subject from which the T cells were obtained. Addition of a PD-I antagonist to such assays would be expected to result in a more potent, and therefore more readily detectable, in vitro response.
• the PD-I antagonists are generally useful in vivo and ex vivo as immune response-stimulating therapeutics.
• the compositions are useful for treating infections in which T cell exhaustion or T cell anergy has occurred causing the infection to remain with the host over a prolonged period of time.
• Exemplary infections to be treated are chronic infections cause by a hepatitis virus, a human immunodeficiency virus (HIV), a human T-lymphotrophic virus (HTLV), a herpes virus, an Epstein- Barr virus, or a human papilloma virus. It will be appreciated that other infections can also be treated using the PD-I antagonists.
• the disclosed compositions are also useful as part of a vaccine.
• the type of disease to be treated or prevented is a chronic infectious disease caused by a bacterium, virus, protozoan, helminth, or other microbial pathogen that enters intracellularly and is attacked, i.e., by cytotoxic T lymphocytes.
• T cell exhaustion is a tolerance mechanism in which the lymphocyte is intrinsically functionally inactivated following an antigen encounter, but remains alive for an extended period of time in a hyporesponsive state.
• One method for treating chronic infection is to revitalize exhausted T cells or to reverse T cell exhaustion in a subject as well as overcoming T cell anergy.
• Reversal of T cell exhaustion can be achieved by interfering with the interaction between PD-I and its ligands PD-Ll (B7-H1) and PD-L2 (PD- L2).
• Acute, often lethal, effects of pathogens can be mediated by toxins or other factors that fail to elicit a sufficient immune response prior to the damage caused by the toxin. This may be overcome by interfering with the interaction between PD-I and its ligands, allowing for a more effective, rapid immune response. Because viral infections are cleared primarily by T-cells, an increase in T-cell activity is therapeutically useful in situations where more rapid or thorough clearance of an infective viral agent would be beneficial to an animal or human subject.
• the PD-I antagonists can be administered for the treatment of local or systemic viral infections, including, but not limited to, immunodeficiency (e.g., HIV), papilloma (e.g., HPV), herpes (e.g., HSV), encephalitis, influenza (e.g., human influenza virus A), and common cold (e.g., human rhinovirus) viral infections.
• immunodeficiency e.g., HIV
• papilloma e.g., HPV
• herpes e.g., HSV
• encephalitis e.g., influenza virus A
• common cold e.g., human rhinovirus
• pharmaceutical formulations including the PD-I antagonist compositions can be administered topically to treat viral skin diseases such as herpes lesions or shingles, or genital warts.
• Pharmaceutical formulations of PD-I antagonist compositions can also be administered to treat systemic viral diseases, including, but not limited to, AIDS, influenza, the common cold
• infections that can be treated include but are not limited to infections cause by microoganisms including, but not limited to, Actinomyces, Anabaena, Bacillus, Bacteroides, Bdellovibrio, Bordetella, Borrelia, Campylobacter, Caulobacter, Chlamydia, Chlorobium, Chromatium, Clostridium, Coryne bacterium, Cytophaga, Deinococcus, Escherichia, Francisella, Halobacterium, Heliobacter, Haemophilus, Hemophilus influenza type B (HIB), Histoplasma, Hyphomicrobium, Legionella, Leishmania, Leptspirosis, Listeria, Meningococcus A, B and C, Methanobacterium, Micrococcus, Myobacterium, Mycoplasma, Myxococcus, Neisseria, Nitrobacter, Oscillatoria, Prochloron, Proteus, Pseudomonas, Phodo
• the PD-I antagonists or nucleic acids encoding the same may be administered alone or in combination with any other suitable treatment.
• the PD-I antagonist can be administered in conjunction with, or as a component of a vaccine composition as described above. Suitable components of vaccine compositions are described above.
• the disclosed PD-I antagonist can be administered prior to, concurrently with, or after the administration of a vaccine.
• the PD-I antagonist composition is administered at the same time as administration of a vaccine.
• PD-I antagonist compositions may be administered in conjunction with prophylactic vaccines, which confer resistance in a subject to subsequent exposure to infectious agents, or in conjunction with therapeutic vaccines, which can be used to initiate or enhance a subject's immune response to a pre-existing antigen, such as a viral antigen in a subject infected with a virus.
• the desired outcome of a prophylactic, therapeutic or de-sensitized immune response may vary according to the disease, according to principles well known in the art.
• an immune response against an infectious agent may completely prevent colonization and replication of an infectious agent, affecting "sterile immunity" and the absence of any disease symptoms.
• a vaccine against infectious agents may be considered effective if it reduces the number, severity or duration of symptoms; if it reduces the number of individuals in a population with symptoms; or reduces the transmission of an infectious agent.
• immune responses against cancer, allergens or infectious agents may completely treat a disease, may alleviate symptoms, or may be one facet in an overall therapeutic intervention against a disease.
• the PD-I antagonists induce an improved effector cell response such as a CD4 T-cell immune response, against at least one of the component antigen(s) or antigenic compositions compared to the effector cell response obtained with the corresponding composition without the PD-I antagonist.
• improved effector cell response refers to a higher effector cell response such as a CD4 response obtained in a human patient after administration of the vaccine composition than that obtained after administration of the same composition without a PD-I antagonist.
• a higher CD4 T-cell response is obtained in a human patient upon administration of an immunogenic composition containing an PD-I antagonist, preferably PD-L2- ⁇ g, and an antigenic preparation compared to the response induced after administration of an immunogenic composition containing the antigenic preparation thereof which is un-adjuvanted.
• an immunogenic composition containing an PD-I antagonist preferably PD-L2- ⁇ g
• an antigenic preparation compared to the response induced after administration of an immunogenic composition containing the antigenic preparation thereof which is un-adjuvanted.
• Such a formulation will advantageously be used to induce anti-antigen effector cell response capable of detection of antigen epitopes presented by MHC class II molecules.
• the improved effector cell response can be obtained in an immunologically unprimed patient, i.e. a patient who is seronegative to the antigen.
• This seronegativity may be the result of the patient having never faced the antigen (so-called "na ⁇ ve” patient) or, alternatively, having failed to respond to the antigen once encountered.
• the improved effector cell response is obtained in an immunocompromised subject such as an elderly, typically 65 years of age or above, or an adult younger than 65 years of age with a high risk medical condition ("high risk" adult), or a child under the age of two.
• the improved effector cell response can be assessed by measuring the number of cells producing any of the following cytokines: (1) cells producing at least two different cytokines (CD40L, ⁇ L-2, IFN-gamma, TNF- alpha); (2) cells producing at least CD40L and another cytokine (IL-2, TNF- alpha, IFN-gamma); (3) cells producing at least IL-2 and another cytokine (CD40L, TNF-alpha, IFN-gamma); (4) cells producing at least IFN-gamma. and another cytokine (IL-2, TNF-alpha., CD40L); (5) and cells producing at least TNF-alpha and another cytokine (IL-2, CD40L, IFN-gamma)
• An improved effector cell response is present when cells producing any of the above cytokines will be in a higher amount following administration of the vaccine composition compared to the administration of the composition without a PD-I antagonist. Typically at least one, preferably two of the five conditions mentioned above will be fulfilled. In a particular embodiment, cells producing all four cytokines will be present at a higher number in the vaccinated group compared to the un-vaccinated group.
• the immunogenic compositions may be administered by any suitable delivery route, such as intradermal, mucosal e.g. intranasal, oral, intramuscular or subcutaneous. Other delivery routes are well known in the art.
• the intramuscular delivery route is preferred for the immunogenic compositions.
• Intradermal delivery is another suitable route. Any suitable device may be used for intradermal delivery, for example short needle devices.
• Intradermal vaccines may also be administered by devices which limit the effective penetration length of a needle into the skin. Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis can also be used. Jet injection devices are known in the art. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis can also be used. Additionally, conventional syringes can be used in the classical Mantoux method of intradermal administration.
• Another suitable administration route is the subcutaneous route.
• Any suitable device may be used for subcutaneous delivery, for example classical needle.
• a needle-free jet injector service is used. Needle-free injectors are known in the art. More preferably the device is pre-filled with the liquid vaccine formulation,
• the vaccine is administered intranasally.
• the vaccine is administered locally to the nasopharyngeal area, preferably without being inhaled into the lungs.
• an intranasal delivery device which delivers the vaccine formulation to the nasopharyngeal area, without or substantially without it entering the lungs.
• Preferred devices for intranasal administration of the vaccines are spray devices. Nasal spray devices are commercially available. Nebulizers produce a very fine spray which can be easily inhaled into the lungs and therefore does not efficiently reach the nasal mucosa. Nebulizers are therefore not preferred.
• Preferred spray devices for intranasal use are devices for which the performance of the device is not dependent upon the pressure applied by the user.
• Pressure threshold devices Liquid is released from the nozzle only when a threshold pressure is applied. These devices make it easier to achieve a spray with a regular droplet size. Pressure threshold devices suitable for use with the present invention are known in the art and are commercially available.
• Preferred intranasal devices produce droplets (measured using water as the liquid) in the range 1 to 200 ⁇ m, preferably 10 to 120 ⁇ m. Below 10 ⁇ m there is a risk of inhalation, therefore it is desirable to have no more than about 5% of droplets below 10 ⁇ m. Droplets above 120 ⁇ m do not spread as well as smaller droplets, so it is desirable to have no more than about 5% of droplets exceeding 120 ⁇ m.
• Bi-dose delivery is another feature of an intranasal delivery system for use with the vaccines.
• Bi-dose devices contain two sub-doses of a single vaccine dose, one sub-dose for administration to each nostril. Generally, the two sub-doses are present in a single chamber and the construction of the device allows the ef ⁇ cient delivery of a single sub-dose at a time.
• a monodose device may be used for administering the vaccines.
• the immunogenic composition may be given in two or more doses, over a time period of a few days, weeks or months.
• different routes of administration are utilized, for example, for the first administration may be given intramuscularly, and the boosting composition, optionally containing a PD-I antagonist, may be administered through a different route, for example intradermal, subcutaneous or intranasal.
• the improved effector cell response conferred by the immunogenic composition may be ideally obtained after one single administration.
• the single dose approach is extremely relevant in a rapidly evolving outbreak situation including bioterror ⁇ st attacks and epidemics.
• the second dose of the same composition (still considered as "composition for first vaccination') can be administered during the on-going primary immune response and is adequately spaced in time from the first dose.
• the second dose of the composition is given a few weeks, or about one month, e.g. 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after the first dose, to help prime the immune system in unresponsive or poorly responsive individuals.
• the administration of the immunogenic composition alternatively or additionally induces an improved B-memory cell response in patients administered with the adjuvanted immunogenic composition compared to the B-memory cell response induced in individuals immunized with the un-adj wanted composition.
• An improved B-memory cell response is intended to mean an increased frequency of peripheral blood B lymphocytes capable of differentiation into antibody-secreting plasma cells upon antigen encounter as measured by stimulation of in vitro differentiation (see Example sections, e.g. methods of Elispot B cells memory).
• the immunogenic composition increases the primary immune response as well as the CD8 response.
• the administration of a single dose of the immunogenic composition for first vaccination provides better sero -protection and induces an improved CD4 T- cell, or CD8 T-cell immune response against a specific antigen compared to that obtained with the un-adjuvanted formulation. This may result in reducing the overall morbidity and mortality rate and preventing emergency admissions to hospital for pneumonia and other influenza-like illness.
• This method allows inducing a CD4 T cell response which is more persistent in time, e.g. still present one year after the first vaccination, compared to the response induced with the un-adjuvanted formulation.
• the CD4 T-cell immune response such as the improved CD4 T-cell immune response obtained in an unprimed subject, involves the induction of a cross-reactive CD4 T helper response.
• the amount of cross-reactive CD4 T cells is increased.
• cross-reactive CD4 response refers to CD4 T-cell targeting shared epitopes for example between influenza strains.
• the dose of PD-I antagonist enhances an immune response to an antigen in a human.
• a suitable PD-I antagonist amount is that which improves the immunological potential of the composition compared to the unadjuvanted composition, or compared to the composition adjuvanted with another PD-I antagonist amount.
• an immunogenic composition dose will range from about 0.5 ml to about 1 ml.
• Typical vaccine doses are 0.5 ml, 0.6 ml, 0.7 ml, 0.8 ml, 0.9 ml or 1 ml.
• a final concentration of 50 ⁇ g of PD-I antagonist is contained per ml of vaccine composition, or 25 ⁇ g per 0.5 ml vaccine dose. In other preferred embodiments, final concentrations of 35.7 ⁇ g or 71.4 ⁇ g of PD-I antagonist is contained per ml of vaccine composition. Specifically, a 0.5 ml vaccine dose volume contains 25 ⁇ g or 50 ⁇ g of PD-I antagonist per dose. In still another embodiment, the dose is 100 ⁇ g or more.
• Immunogenic compositions usually contain 15 ⁇ g of antigen component as measured by single radial immunodiffusion (SRD) (J. M. Wood et al.: J. Biol. Stand. 5 (1977) 237-247; J. M. Wood et al., J. Biol Stand. 9 (1981) 317-330).
• Subjects can be revaccinated with the immunogenic compositions. Typically revaccination is made at least 6 months after the first vaccination(s), preferably 8 to 14 months after, more preferably at around 10 to 12 months after.
• the immunogenic composition for revaccination may contain any type of antigen preparation, either inactivated or live attenuated. It may contain the same type of antigen preparation, for example split influenza virus or split influenza virus antigenic preparation thereof, a whole virion, a purified subunit vaccine or a virosome, as the immunogenic composition used for the first vaccination.
• the boosting composition may contain another type of antigen, i.e. split influenza virus or split influenza virus antigenic preparation thereof, a whole virion, a purified subunit vaccine or a virosome, than that used for the first vaccination.
• a boosting composition is typically given at the next viral season, e.g. approximately one year after the first immunogenic composition.
• the boosting composition may also be given every subsequent year (third, fourth, fifth vaccination and so forth).
• the boosting composition may be the same as the composition used for the first vaccination.
• revaccination induces any, preferably two or all, of the following: (i) an improved effector cell response against the antigenic preparation, or (ii) an improved B cell memory response or (iii) an improved humoral response, compared to the equivalent response induced after a first vaccination with the antigenic preparation without a PD-I antagonist.
• the immunological responses induced after revaccination with the immunogenic antigenic preparation containing the PD-I antagonist are higher than the corresponding response induced after the revaccination with the un-adjuvanted composition.
• the immunogenic compositions can be monovalent or multivalent, i.e, bivalent, trivalent,or quadrivalent. Preferably the immunogenic composition thereof is trivalent or quadrivalent.
• Multivalent refers to the number of sources of antigen, typically from different species or strains. With regard to viruses, at least one strain is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak.
• Another embodiment provides contacting antigen presenting cells (APCs) with one or more of the disclosed PD-I antagonists in an amount effective to inhibit, reduce or block PD-I signal transduction in the APCs.
• APCs antigen presenting cells
• Blocking PD-I signal transduction in the APCs reinvigorates the APCs enhancing clearance of intracellular pathogens, or cells infected with intracellular pathogens.
• the PD-I antagonist compositions can be administered to a subject in need thereof alone or in combination with one or more additional therapeutic agents.
• the additional therapeutic agents are selected based on the condition, disorder or disease to be treated.
• aPD-1 antagonist can be co-administered with one or more additional agents that function to enhance or promote an immune response.
• Binding properties of the PD-I antagonists are relevant to the dose and dose regime to be administered.
• Existing antibody PD-I antagonists such as MDX- 1106 demonstrate sustained occupancy of 60-80% of PD-I molecules on T cells for at least 3 months following a single dose (Brahmer, et al. J. Clin. Oncology, 27:(155) 3018 (2009)).
• the disclosed PD-I antagonists have binding properties to PD-I that demonstrate a shorter term, or lower percentage, of occupancy of PD-I molecules on immune cells.
• the disclosed PD-I antagonists typically show less than S 5 1O 5 15, 20, 25, 30, 35, 40 s 45, of 50% occupancy of PD-I molecules on immune cells after one week, two weeks, three weeks, or even one month after administration of a single dose.
• the disclosed PD-I antagonists have reduced binding affinity to PD-I relative to MDX-1106.
• the PD-I-Ig fusion protein In relation to an antibody such as MDX- 1106, the PD-I-Ig fusion protein has a relatively modest affinity for its receptor, and should therefore have a relatively fast off rate.
• the PD-I antagonists are administered intermittently over a period of days, weeks or months to elicit periodic enhanced immune response which are allowed to diminish prior to the next administration, which may serve to initiate an immune response, stimulate an immune response, or enhance an immune response.
• Example 1 B7-DC binding to PD-I PD-I binding activity of human B7-DC-Ig was assessed by ELISA. 96-well ELISA plates were coated with 100 ⁇ L 0.75 ug/mL recombinant human PD-I /Fc (R&D Systems) diluted in BupH Carbonate/Bicarbonate pH 9.4 buffer (Pierce) for 2 hours and then blocked with BSA solution (Jackson ImmunoResearch) for 90-120 minutes. Serially diluted human B7-DC-Ig as well as human IgGl isotype control were allowed to bind for 90 minutes.
• Bound B7-DC- ⁇ g was detected using 100 uL of 0.5 ug/mL biotin conjugated anti-human B7-DC clone MIH 18 (eBioscience) followed by 1:1000 diluted HRP-Streptavidin (BD Bioscience) and TMB substrate (BioFX). Absorbance at 450 nm was read using a plate reader (Molecular Devices) and data were analyzed in SoftMax using a 4-parameter logistic fit.
• PD-I binding activity of murine B7-DC-Ig was assessed by ELISA.
• 96-well ELISA plates were coated with 100 ⁇ L 0.75 ug/mL recombinant mouse PD-l/Fc (R&D Systems) diluted in BupH Carbonate/Bicarbonate pH 9.4 buffer (Pierce) for 2 hours and then blocked with BSA solution (Candor- Bioscience) for 90 minutes.
• Serially diluted murine B7-DC-Ig wild type, as well as Dl 11 S and KI l 3 S mutants that were selected for reduced binding to PD-I
• murine IgG2a isotype control were allowed to bind for 90 minutes.
• Bound B7-DC-Ig was detected using 100 uL of 0.25 ug/mL biotin conjugated anti-mouse B7-DC clone 112 (eBioscience) followed by 1 :2000 diluted HRP-Streptavidin (BD Bioscience) and TMB substrate (BioFX). Absorbance at 450 nm was read using a plate reader (Molecular Devices) and data were analyzed in SoftMax using a 4-parameter logistic fit.
• Figures IA and IB show line graphs of OD4 50 versus amount of B7- DC-Ig (ug/ml) in a PD-I binding ELISA.
• Figure IA shows binding of four different lots of human B7-DC-Ig.
• Figure IB shows binding of wild type murine B7-DC-Ig (circle), the DS mutant (B7-DC-Ig with the Dl I l S substitution; triangle) and KS mutant (B7-DC-Ig with the Kl 13S substitution; square), and murine IgG2a isotype control (diamond).
• Example 2 B7-DC binding to PD-I expressing CHO cells
• B7-DC-Ig was first conjugated with allophycocyanin (APC) and then incubated at various concentrations with a CHO cell line constitutively expressing PD-I or parent CHO cells that do not express PD-L Binding was analyzed by flow cytometry.
• Figure 2 shows the median fluorescence intensity (MFI) of B7-DC-Ig-APC (y-axis) as a function of the concentration of probe (x-axis).
• MFI median fluorescence intensity
• B7-DC-Ig-APC binds to CHO.PD-1 cells (solid circle) but not untransfected CHO cells (gray triangle).
• B7-Hl-Ig was first conjugated with allophycocyanin (APC). Unlabeled B7-DC-Ig at various concentrations was first incubated with a CHO cell line constitutively expressing PD-I before adding B7-H1 -Ig-APC to the probe and cell mixture.
• Figure 3 shows the median fluorescence intensity (MFI) of B7-H1 -Ig-APC (y-axis) as a function of the concentration of unlabeled B7-DC-Ig competitor (x-axis) added.
• MFI median fluorescence intensity
• B7-DC-Ig As the concentration of unlabeled B7-DC-Ig is increased the amount of B7-H1 -Ig-APC bound to CHO cells decreases, demonstrating that B7-DC-Ig competes with B7-H1 for binding to PD-L
• Example 4 Combination of cyclophosphamide and B7-DC-Ig can generate tumor specific, memory cytotoxic T lymphocytes
• mice at age of 9 to 1 1 weeks were implanted subcutaneously with 1.0 x 105 CT26 colorectal tumor cells. On day 10 post tumor implantation, mice received 100 mg/kg of cyclophosphamide. B7-DC-Ig treatment started 1 day later, on day 11. Mice were treated with 100 ug of B7-DC-Ig, 2 doses per week, for 4 weeks and total 8 doses. 75% of the mice that received the CTX + B7-DC-Ig treatment regimen eradicated the established tumors by Day 44, whereas all mice in the control CTX alone group died as a result of tumor growth or were euthanized because tumors exceeded the sizes approved by IACUC .
• mice eradiated established CT26 colorectal tumors from the above described experiment were rechallenged with 2.5x105 CT26 cells on Day 44. Seven days later, mouse spleens were isolated. Mouse splenocytes were pulsed with 5 or 50 ug/mL of ovalbumin (OVA) or AHl peptides for 6 hours in the presence of a Golgi blocker (BD BioScience). Memory T effector cells were analyzed by assessing CD8+/IFN ⁇ + T cells. Results in Figure 4 show that there were significant amount of CT26 specific T effector cells in the CT26 tumor-eradicated mice.
• OVA ovalbumin
• AHl peptides AHl peptides
• Example 5 B7-DC-Ig reduced HSV viral particle shedding and enhanced mouse survival.
• mice at age of 8 to 10 weeks were first immunized with a live attenuated HSV-2 vaccine at a dose of 4x10 4 PFU together with vehicle (open square) or 300 ⁇ g of B7-DC-Ig (solid square) ( Figures 2A and 2B).
• Figures 2A and 2B One month later, all the mice were challenged with 5x10 5 PFU of HSV-2 strain G-6 intravaginally.
• Figure 5 A reveals viral particle titers of swabs of vaginal area at 9 hr, 1, 2, 3, 4, and 5 days post virus challenge.
• Figure 5B shows mouse survival on day 12 post virus challenge. This demonstrates that the presence B7-DC-Ig in combination with a vaccine can reduce viral load and increase survival of animals.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Zoology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Virology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Toxicology (AREA)
• Epidemiology (AREA)
• Biomedical Technology (AREA)
• Cell Biology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Wood Science & Technology (AREA)
• Tropical Medicine & Parasitology (AREA)
• General Engineering & Computer Science (AREA)
• Mycology (AREA)
• Physics & Mathematics (AREA)
• Plant Pathology (AREA)
• Endocrinology (AREA)
• AIDS & HIV (AREA)

Priority Applications (4)

Applications Claiming Priority (12)

Related Child Applications (2)

Publications (2)

Family

ID=41349286

Family Applications (3)

Family Applications After (2)

Country Status (13)

Cited By (22)

Families Citing this family (826)